Gadsden Properties (GADS) 10-Q 11 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	11-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	PHOTOMEDEX INC
Entity Central Index Key	711665
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		22,076,718
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$6,199	$10,605
Short term bank deposit	0	87
Accounts receivable, net of allowance for doubtful accounts of $13,846 and $13,559, respectively	15,717	21,977
Inventories, net	19,863	19,380
Deferred tax asset, net	750	762
Prepaid expenses and other current assets	8,234	8,347
Assets held for sale, net	0	70,855
Total current assets	50,763	132,013
Property and equipment, net	14,547	13,802
Patents and licensed technologies, net	8,253	8,811
Other intangible assets, net	7,936	8,337
Goodwill, net	23,404	24,048
Deferred tax asset, net	587	567
Other assets, net	178	185
Total assets	105,668	187,763
Current liabilities:
Current portion of notes payable	801	704
Current portion of long term debt	3,000	38,732
Accounts payable	12,339	12,419
Accrued compensation and related expenses	2,811	2,622
Other accrued liabilities	10,371	13,022
Current portion of deferred revenues	3,998	4,480
Liabilities held for sale	0	34,497
Total current liabilities	33,320	106,476
Long-term liabilities:
Notes payable, net of current maturities	11	25
Long term debt, net of current maturities	37,018	37,768
Deferred revenues, net of current portion	876	1,127
Other liabilities	148	102
Total liabilities	71,373	145,498
Commitments and Contingencies (Note 12)
Stockholders' equity:
Preferred Stock, $.01 par value, 5,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2015 and December 31, 2014	0	0
Common Stock, $.01 par value, 50,000,000 shares authorized; 22,076,718 and 20,376,245 shares issued and outstanding, respectively	221	204
Additional paid-in capital	113,627	110,391
Accumulated deficit	-77,830	-67,817
Accumulated other comprehensive loss	-1,723	-513
Total stockholders' equity	34,295	42,265
Total liabilities and stockholders' equity	$105,668	$187,763

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Current assets:
Accounts receivable, allowance for doubtful accounts	$13,846	$13,559
Stockholders' Equity
Preferred Stock, par value (in dollars per share)	$0.01	$0.01
Preferred Stock, authorized (in shares)	5,000,000	5,000,000
Preferred Stock, issued (in shares)	0	0
Preferred Stock, outstanding (in shares)	0	0
Common Stock, par value (in dollars per share)	$0.01	$0.01
Common Stock, authorized (in shares)	50,000,000	50,000,000
Common Stock, issued (in shares)	22,076,718	20,376,245
Common Stock, outstanding (in shares)	22,076,718	20,376,245

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Unaudited) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Product sales	$22,773	$45,665
Services	5,376	4,410
Total revenues	28,149	50,075
Cost of revenues:
Product sales	5,944	8,608
Services	1,978	1,737
Total cost of revenues	7,922	10,345
Gross profit	20,227	39,730
Operating expenses:
Engineering and product development	755	795
Selling and marketing	20,132	31,625
General and administrative	4,729	7,587
Total operating expenses	25,616	40,007
Loss from continuing operations before interest and other financing expense, net	-5,389	-277
Interest and other financing expense, net	-2,551	-147
Loss from continuing operations before income taxes	-7,940	-424
Income tax (expense) benefit	-365	79
Loss from continuing operations	-8,305	-345
Discontinued operations:
Loss from discontinued operations, net of taxes	-1,667	0
Loss on sale of discontinued operations	-41	0
Net loss	-10,013	-345
Basic net loss per share:
Continuing operations (in dollars per share)	($0.42)	($0.02)
Discontinued operations (in dollars per share)	($0.09)	$0
Basic (in dollars per share)	($0.51)	($0.02)
Diluted net loss per share:
Continuing operations (in dollars per share)	($0.42)	($0.02)
Discontinued operations (in dollars per share)	($0.09)	$0
Diluted (in dollars per share)	($0.51)	($0.02)
Shares used in computing net loss per share:
Basic (in shares)	19,794,210	18,719,419
Diluted (in shares)	19,794,210	18,719,419
Other comprehensive (loss) income :
Foreign currency translation adjustments	-1,210	337
Comprehensive loss	($11,223)	($8)

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited) (USD $)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
In Thousands, except Share data, unless otherwise specified
BALANCE at Dec. 31, 2014	$204	$110,391	($67,817)	($513)	$42,265
BALANCE (in shares) at Dec. 31, 2014	20,376,245				20,376,245
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation related to stock options and restricted stock, including accelerated vesting for discontinued operations	17	3,320	0	0	3,337
Stock-based compensation related to stock options and restricted stock, including accelerated vesting for discontinued operations (in shares)	1,700,473
Registration costs	0	-84	0	0	-84
Other comprehensive loss	0	0	0	-1,210	-1,210
Net loss	0	0	-10,013	0	-10,013
BALANCE at Mar. 31, 2015	$221	$113,627	($77,830)	($1,723)	$34,295
BALANCE (in shares) at Mar. 31, 2015	22,076,718				22,076,718

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash Flows From Operating Activities:
Net loss	($10,013)	($345)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,865	1,636
Provision for doubtful accounts	406	813
Deferred income taxes	-47	857
Stock-based compensation	974	1,262
Gain disposal of property and equipment	0	-10
Financing expense	1,481	0
Changes in operating assets and liabilities:
Accounts receivable	5,687	4,367
Inventories	-624	571
Prepaid expenses and other assets	330	-280
Accounts payable	-1,487	-5,837
Accrued compensation and related expenses	200	-641
Other accrued liabilities (see Note 9)	-2,518	-6,383
Other liabilities	1	42
Deferred revenues	-712	-538
Net cash used in operating activities - continuing operations	-4,457	-4,486
Net cash provided by operating activities - discontinued operations	541	0
Net cash used in operating activities	-3,916	-4,486
Cash Flows From Investing Activities:
Purchases of property and equipment	-31	-85
Lasers placed in service	-1,758	-1,717
Proceeds from (investments in) short-term deposit	87	-4,235
Proceeds on sale of property and equipment	0	20
Acquisition, net of cash received	0	-42
Net cash used in investing activities - continuing operations	-1,702	-6,059
Net cash provided by investing activities - discontinued operations	38,245	0
Net cash provided by (used in) investing activities	36,543	-6,059
Cash Flows From Financing Activities:
Registration costs	-84	0
Repayment of debt	-36,478	0
Payments on notes payable	-189	-224
Repayment of short-term debt	0	-5,000
Net cash used in financing activities - continuing operations	-36,751	-5,224
Net cash used in financing activities - discontinued operations	-66	0
Net cash used in financing activities	-36,817	-5,224
Effect of exchange rate changes on cash	-216	105
Net decrease in cash and cash equivalents	-4,406	-15,664
Cash and cash equivalents, beginning of period	10,605	45,388
Cash and cash equivalents, end of period	6,199	29,724
Supplemental information:
Cash paid for income taxes	97	405
Cash paid for interest	$1,182	$47

The_Company

The Company	3 Months Ended
	Mar. 31, 2015
The Company [Abstract]
The Company	Note 1
	The Company:
	Background
	PhotoMedex, Inc. (and its subsidiaries) (the "Company") is a Global Skin Health company providing integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers. The Company provides proprietary products and services that address skin diseases and conditions including psoriasis, vitiligo, acne, actinic keratosis (a precursor to certain types of skin cancer), photo damage and unwanted hair.
	On May 12, 2014, PhotoMedex completed the acquisition of 100% of the shares of LCA-Vision Inc. ("LCA-Vision" or "LCA"), which was a publicly–traded Delaware corporation. LCA is a provider of fixed-site laser vision corrections services at its Lasik Plus® vision centers. Through this acquisition, the Company intended to add an additional operating segment to its organization. The Company planned to begin to directly market certain of its existing products from these centers. The results of operations of LCA-Vision have been included from May 13, 2014 through January 31, 2015 into the Company's consolidated financial statements as a discontinued operation. (See Note 3, Acquisition of LCA-Vision Inc.).
	On January 31, 2015, the Company sold 100% of the shares of LCA-Vision Inc. for $40 million in cash. Excluding working capital adjustments and professional fees, the Company realized net proceeds of approximately $37.7 million, substantially all of which were used to repay indebtedness. The LCA-Vision assets and liabilities were considered to be held for sale as of December 31, 2014. For the statement of operations, for the three months ended March 31, 2015, the activity related to LCA's operations through the date of disposition, and any gains or losses therefrom, are captured as discontinued operations. (See Note 2, Discontinued Operations.)
	On May 12, 2014, the Company entered into an $85 million senior secured credit facilities ("the Facilities") with JP Morgan Chase ("Chase") which included a $10 million revolving credit facility and a $75 million four-year term loan. The facilities were utilized to refinance the existing term debt with Chase, fund the acquisition of LCA and for working capital and other general corporate purposes.
	Effective February 28, 2015, the Company entered into a Second Amended and Restated Forbearance Agreement (the "Second Amended Forbearance Agreement") with the lenders that are parties to the Credit Agreement dated May 12, 2014, and with Chase, as Administrative Agent for the Lenders.
	Pursuant to the terms of the Second Amended Forbearance Agreement, the Lenders have agreed to forbear from exercising their rights and remedies with respect to the Specified Events of Default from August 25, 2014 until April 1, 2016, or earlier if any new event of default occurs (the "Forbearance Period"). Chase and the Lenders agreed that the Company shall not be obligated to pay the principal amounts set forth in the Credit Agreement for any date identified therein during the period beginning on February 28, 2015 and ending on the end of the Forbearance Period (the "Effective Period"), and that any failure to do so shall not constitute a default or event of default. Instead, the Lenders and the Company agreed that the Company would make prepayments against the Term Loan of $250,000 on the first business day of each month during the Forbearance Period, which will be applied in direct order of maturity. The Company also agreed that, on or before the fifth calendar day of each month, the Company would pay against the Term Loan $125,000 to the extent that the cash-on-hand exceeds $5 million, and 100% of the cash-on-hand in excess of $7 million, also to be applied to the Term Loan in inverse order of maturity.
	Under the provisions of the Second Amended Forbearance Agreement, the Company will not have to comply with certain financial covenants contained in the Credit Agreement for the Forbearance Period, and that any failure to do so shall not constitute a default or event of default. However, the Company has to meet certain minimum EBITDA targets (as defined in the forbearance agreement) for the quarters ending March 31, 2015, June 30, 2015, September 30, 2015 and December 31, 2015. The Company has met the EBITDA target as of March 31, 2015.
	Pursuant to the Second Amended Forbearance Agreement, all loans under the Facilities shall, beginning November 1, 2014, bear interest at the CB Floating Rate (as defined in the Credit Agreement) plus 4.00%. Additionally, following the occurrence and continuance of any default or event of default (other than a Specified Event of Default), the Company's obligations under the Facilities shall, at the option of Chase and the Lenders, bear interest at the rate of 2.00% plus the rate otherwise in effect.
	The Company and its subsidiaries have also agreed not to pay in cash any compensation to either the Company's Chief Executive Officer or President that is based on a percentage of sales or another metric other than those officer's base salary, perquisites and standard benefits provided to or on behalf of those executives under the terms of their employment agreements. Those payments may be accrued or deferred and paid in cash only after the repayment of the Facilities in full.
	The Company has agreed to provide, on or before May 29, 2015, a strategic business plan for the overall direction of the Company's and its subsidiaries' businesses, including projected income statements, balance sheets, schedules of cash receipts and cash disbursements, payments and month-end balances, and detailed notes and assumptions, projected on a monthly basis through April 1, 2016. The Company has also agreed to provide quarterly updates to that plan by August 31, 2015, November 30, 2015 and February 29, 2016.
	The Company continues to retain the services of both Getzler Henrich & Assoc. LLC, a third-party independent business advisor, as well as Canaccord Genuity, Inc., a banking and financial services company, and has also retained the services of Nomura Securities International, Inc., also a banking and financial services company. During the Forbearance Agreement and amendments, the Company and these advisors will continue to prepare and distribute offering memoranda and other marketing materials to prospective lenders with regard to a proposed credit facility for the Company, the proceeds of which would be in an amount sufficient to repay in full and in cash the Company's remaining obligations under the Facilities, and to explore other strategic alternatives. The closing of any such refinancing or alternative arrangement would occur no later than the end of the Forbearance Period.
	The Company agreed to limit certain capital expenditures to $100,000 per quarter, except for those involving the Company's XTRAC ® or VTRAC ®  medical devices, and will not make investments or acquire any other interests in affiliated companies except as agreed to by the Lenders.
	As consideration for the Lender's entry into the Second Amended Forbearance Agreement, the Company has agreed to pay the Lenders certain forbearance fees (the "Forbearance Fees"), which are earned on the last business day of each of the specified months: for May and June 2015, $750,000 each month; for July through September 2015, $1,000,000 each month; for October through December 2015, $1,250,000 each month; and for January through March 2016, $1,500,000 each month. However, should the Company complete a capital transaction acceptable to the Lenders that reduces the then-outstanding principal balance of the Term Loan to less than $10 million and repays all Forbearance Fees accrued and unpaid to that date, the monthly Forbearance Fee for the remainder of the Forbearance Period shall be earned and accrued in an amount that is 50% of the amount specified for each of the remaining months. In addition, the $500,000 Forbearance Fee set forth in Section 4.10(b) of the Amended Forbearance Agreement remains due and payable to the Lenders on the earlier of the Expiration Date or the Termination Date of the Forbearance Period.
	The Second Amended Forbearance Agreement is also subject to customary covenants, including limitations on the incurrence of or payments on indebtedness to other persons or entities and requirements that the Company provide periodic financial information and information regarding the status of outstanding litigation involving the Company and its subsidiaries to the Lenders. As of March 31, 2015, the Company is in compliance with these covenants.
	Basis of Presentation:
	Accounting Principles
	The accompanying condensed consolidated financial statements and related notes should be read in conjunction with our consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 ("fiscal 2014"). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company's financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.
	The results for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015 or for any other interim period or for any future period.
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and the wholly- and majority-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
	Held for Sale Classification and Discontinued Operations
	A disposal group is reported as held for sale when management has approved or received approval to sell and is committed to a formal plan, the disposal group is available for immediate sale, the business is being actively marketed, the sale is anticipated to occur during the next 12 months and certain other specified criteria are met. A disposal group classified as held for sale is recorded at the lower of its carrying amount or estimated fair value less cost to sell. If the carrying value of the business exceeds its estimated fair value less cost to sell, a loss is recognized. However, when disposal group meets the held for sale criteria, the Company, first evaluates whether the carrying amounts of the assets not covered by ASC 360-10 included in the disposal group (such as goodwill) are required to be adjusted in accordance with other applicable GAAP before measuring the disposal group at fair value less cost to sell.
	Assets and liabilities related to a disposal group classified as held for sale are segregated in the consolidated balance sheet in the period in which the business is classified as held for sale.
	Operations of a disposal group are reported as discontinued operations if the disposal group is classified as held for sale, the operations and cash flows of the business have been or will be eliminated from our ongoing operations as a result of a disposal transaction and we will not have any significant continuing involvement in the operations of the business after the disposal transaction. See below regarding change to the criteria for reporting discontinued operations.
	The results of discontinued operations are reported in discontinued operations in the consolidated statement of operations for current and prior periods commencing in the period in which the business meets the criteria of a discontinued operation, and include any gain or loss recognized on closing or adjustment of the carrying amount to fair value less cost to sell. Depreciation is not recorded on assets of a business while it is classified as held for sale.
	At December 31, 2014, held for sale assets and liabilities consisted of the LCA operating segment, and its results of operations were presented as discontinued operations in the consolidated statement of operations in the periods ended December 31, 2014 and March 31, 2015 (see also Note 2 Discontinued Operations).
	Revenue Recognition
	The Company recognizes revenues from product sales when the following four criteria have been met: (i) the product has been delivered and the Company has no significant remaining obligations; (ii) persuasive evidence of an arrangement exists; (iii) the price to the buyer is fixed or determinable; and (iv) collection is reasonably assured. Revenues from product sales are recorded net of provisions for estimated chargebacks, rebates, expected returns and cash discounts.
	The Company ships most of its products FOB shipping point, although from time to time certain customers, for example governmental customers, will be granted FOB destination terms. Among the factors the Company takes into account when determining the proper time at which to recognize revenue are (i) when title to the goods transfers and (ii) when the risk of loss transfers. Shipments to distributors or physicians that do not fully satisfy the collection criteria are recognized when invoiced amounts are fully paid or fully assured and included in deferred revenues until that time.
	For revenue arrangements with multiple deliverables within a single, contractually binding arrangement (usually sales of products with separately priced extended warranty), each element of the contract is accounted for as a separate unit of accounting when it provides the customer value on a stand-alone basis and there is objective evidence of the fair value of the related unit.
	With respect to sales arrangements under which the buyer has a right to return the related product, revenue is recognized only if all the following conditions are met: the price is fixed or determinable at the date of sale; the buyer has paid, or is obligated to pay and the obligation is not contingent on resale of the product; the buyer's obligation would not be changed in the event of theft or physical destruction or damage of the product; the buyer has economic substance; the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer; and the amount of future returns can be reasonably estimated.
	The Company provides a provision for product returns based on the experience with historical sales returns, in accordance with ASC Topic 605-15 with respect to sales of product when a right of return exists. Reported revenues are shown net of the returns provision. Such allowance for sales returns is included in Other Accrued Liabilities. (See Note 9).
	Deferred revenue includes amounts received with respect to extended warranty maintenance, repairs and other billable services and amounts not yet recognized as revenues. Revenues with respect to such activities are deferred and recognized on a straight-line basis over the duration of the warranty period, the service period or when service is provided, as applicable to each service.
	The Company has two distribution channels for its phototherapy treatment equipment. The Company either (i) sells its lasers through a distributor or directly to a physician or (ii) places its lasers in a physician's office (at no charge to the physician) and generally charges the physician a fee for an agreed upon number of treatments. In some cases, the Company and the customer stipulate to a quarterly or other periodic target of procedures to be performed, and accordingly revenue is recognized ratably over the period.
	When the Company places a laser in a physician's office, it generally recognizes service revenue based on the number of patient treatments performed, or purchased under a periodic commitment, by the physician. Amounts collected with respect to treatments to be performed through laser-access codes that are sold to physicians free of a periodic commitment, but not yet used, are deferred and recognized as a liability until the physician performs the treatment. Unused treatments remain an obligation of the Company because the treatments can only be performed on Company-owned equipment. Once the treatments are performed, this obligation has been satisfied.
	The Company defers substantially all revenue from sales of treatment codes ordered by and performed to its customers within the last two weeks of the period in determining the amount of procedures performed by its physician-customers. Management believes this approach closely approximates the actual amount of unused treatments that existed at the end of a period.
	Functional Currency
	The currency of the primary economic environment in which the operations of the Company, its U.S. subsidiaries and Radiancy Ltd., its subsidiary in Israel, are conducted is the US dollar ("$" or "dollars"). Thus, the functional currency of the Company and its subsidiaries (other than the foreign subsidiaries mentioned below) is the dollar (which is also the reporting currency of the Group). The operations of the other foreign subsidiaries are each conducted in the local currency of the subsidiary. These currencies include: Great Britain Pounds (GBP), Brazilian Real (BRL), Hong Kong Dollar (HKD), Columbian Peso (COP), South Korean Won (KRW) and Indian Rupee (INR). Substantially all of the Group's revenues are derived in dollars or in other currencies linked to the dollar. Purchases of most materials and components are carried out in, or linked to the dollar.
	Balances denominated in, or linked to, foreign currencies are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the statement of comprehensive income (loss), the exchange rates applicable to the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses.
	Assets and liabilities of foreign subsidiaries, whose functional currency is their local currency, are translated from their respective functional currency to U.S. dollars at the balance sheet date exchange rates. Income and expense items are translated at the average rates of exchange prevailing during the year. Translation adjustments are reflected in the consolidated balance sheets as a component of accumulated other comprehensive income (loss). Deferred taxes are not provided on translation adjustments as the earnings of the subsidiaries are considered to be permanently reinvested.
	Fair Value Measurements
	The Company measures and discloses fair value in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification 820, Fair Value Measurements and Disclosures ("ASC Topic 820"). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
		•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
		•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
		•	Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors
	This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.
	The fair value of cash and cash equivalents and short term bank deposits are based on its demand value, which is equal to its carrying value. The estimated fair values of notes payable and long term debt which are based on borrowing rates that are available to the Company for loans with similar terms, collateral and maturity approximate the carrying values. Additionally, the carrying value of all other monetary assets and liabilities is estimated to be equal to their fair value due to the short-term nature of these instruments.
	Derivative financial instruments are measured at fair value, on a recurring basis. The fair value of derivatives generally reflects the estimated amounts that the Group would receive or pay to terminate the contracts at the reporting dates, based on the prevailing currency prices and the relevant interest rates. Such measurement is classified within Level 2.
	In addition to items that are measured at fair value on a recurring basis, there are also assets and liabilities that are measured at fair value on a nonrecurring basis. Assets and liabilities that are measured at fair value on a nonrecurring basis include certain long-lived assets, including goodwill. As such, we have determined that each of these fair value measurements reside within Level 3 of the fair value hierarchy.
	Derivatives
	The Company applies the provisions of Accounting Standards Codification ("ASC") Topic 815, Derivatives and Hedging. In accordance with ASC Topic 815, all the derivative financial instruments are recognized as either financial assets or financial liabilities on the balance sheet at fair value. The accounting for changes in the fair value of a derivative financial instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For derivative financial instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation.
	From time to time the Company carries out transactions involving foreign exchange derivative financial instruments (mainly forward exchange contracts) which are expected to be paid with respect to forecasted expenses of the Israeli subsidiary (Radiancy) denominated in Israeli local currency (NIS) which is different than its functional currency.
	Such derivatives were not designated as hedging instruments, and accordingly they were recognized in the balance sheet at their fair value, with changes in the fair value carried to the Statement of Comprehensive Income (Loss) and included in interest and other financing expenses, net.
	At March 31, 2015, the balance of such derivative instruments amounted to approximately $468 in assets and approximately $206 were recognized as financing income in the Statement of Comprehensive (Loss) Income during the quarter ended that date.
	The nominal amounts of foreign currency derivatives as of March 31, 2015 consist of forward transactions for the exchange of $7,200 into NIS as of March 31, 2015.
	Accrued Warranty Costs
	The Company offers a standard warranty on product sales generally for a one to two-year period. In the case of domestic sales of XTRAC lasers, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold. Total accrued warranty is included in Other Accrued Liabilities on the balance sheet. The activity in the warranty accrual during the three months ended March 31, 2015 and 2014 is summarized as follows:
			March 31,
			2015			2014
			(unaudited)			(unaudited)
	Accrual at beginning of year		$	761		$	1,151
Additions charged to warranty expense			271			256
Expiring warranties			(102	)		(69	)
Claims satisfied			(116	)		(247	)
Total			814			1,091
Less: current portion			(673	)		(1,021	)
Accrued extended warranty		$	141		$	70
For extended warranty on the consumer products, see Revenue Recognition above.
Earnings Per Share
Basic and diluted earnings per common share were calculated using the following weighted-average shares outstanding:
		For the Three Months Ended March 31,
		2014			2014
Weighted-average number of common and common equivalent shares outstanding:
Basic number of common shares outstanding			19,794,210			18,719,419
Dilutive effect of stock options and warrants			-			-
Diluted number of common and common stock equivalent shares outstanding			19,794,210			18,719,419
Diluted earnings per share for the three months ended March 31, 2015, exclude the impact of common stock options and warrants, totaling 3,563,503 shares, as the effect of their inclusion would be anti-dilutive, due to the net loss for the period. Diluted earnings per share for the three months ended March 31, 2014, excluded the impact of common stock options and warrants, totaling 2,444,016 shares, as the effect of their inclusion would be anti-dilutive, due to the net loss for the period.
Adoption of New Accounting Standards
In April 2014, the FASB issued Accounting Standard Update 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity ("ASU 2014-08").
The amendments in ASU 2014-08 change the criteria for reporting discontinued operations while enhancing disclosures in this area. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization's operations and financial results. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations.
The provisions of ASU 2014-08 were required to be applied in a prospective manner to disposals or classifications as held for sale components of an entity that occur with annual periods beginning on or after December 15, 2014 and interim periods within those years.
The company applied the provisions of ASU 2014-08 in the first quarter of 2015.
The adoption of ASU 2014-08 did not have a material impact on the Company's consolidated results of operations and financial condition and also did not affect disposals or classifications as held for sale, of components (such as the sale of LCA) that occurred before the provisions of ASU 2014-08 became effective.
Recently Issued Accounting Standards
In May 2014, The FASB issued Accounting Standard Update 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09").
ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.
An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures.
For a public entity, the amendments in ASU 2014-09 are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early application is not permitted. The Company is in the process of assessing the impact, if any, of ASU 2014-09 on its consolidated financial statements.
In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 provide guidance on management's responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 also provide guidance related to the required disclosures as a result of management evaluation. The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.

Discontinued_Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2015
Discontinued Operations [Abstract]
Discontinued Operations	Note 2
	Discontinued Operations:
	LCA, acquired by the Company on May 12, 2104, is a provider of fixed-site laser vision corrections services at its LasikPlus® vision centers. The vision centers provide the staff, facilities, equipment and support services for performing laser vision correction that employs advanced laser technologies to help correct nearsightedness, farsightedness and astigmatism. The vision centers are supported by independent ophthalmologists and credentialed optometrists, as well as other healthcare professionals. Substantially all of LCA's revenues are derived from the delivery of laser vision correction procedures performed in the vision centers. After preliminary investigations and discussions, the Board of Directors of the Company, with the aid of its investment banker, had reached a formal decision during December 2014 to enter into, substantive, confidential discussions with potential third-party buyers and began to develop plans for implementing a disposal of the assets and operations of the business. The Company accordingly classified this former segment as held for sale in accordance and discontinued operations with ASC Topic 360. On February 2, 2015, the Company closed on sale transaction of 100% of the shares of LCA for $40 million in cash. Excluding estimated working capital adjustments and direct expenses (professional fees to third parties), the Company realized net proceeds of approximately $37.7 million which amount is considered as the fair value less cost to sell of LCA. The sale was effective January 31, 2015. No income tax benefit was recognized by the Company from the loss on the sale of discontinued operations.
	The accompanying condensed consolidated financial statements reflect the operating results and balance sheet items of the discontinued operations separately from continuing operations. Also, as of December 31, 2014, balance sheet items related to LCA were presented as assets held for sale and as liabilities held for sale respectively. The Company recognized an estimated loss of $44,598 on the sale of the discontinued operations in the year ended December 31, 2014, which included a decrease in the implied fair value of goodwill, related to LCA, of $43,091. The remaining loss of $1,507 represents the difference between the adjusted net purchase price and the carrying value of the disposal group. The impairment amount is categorized as level 3 measurements. For the three months ended March 31, 2015, the Company recorded an adjustment of $41 on the sale of the discontinued operations of LCA.
	Revenues from LCA, reported as discontinued operations, for the three months ended March 31, 2015 was $9,158. Loss from LCA, reported as discontinued operations, for the three months ended March 31, 2015 was $1,667, which includes stock compensation of $2,363 related to the contractual acceleration of vesting of awards then outstanding to employees from LCA, included as a result of acceleration of vesting periods, due to the sale of LCA.
	The following is a summary of assets and liabilities held for sale in the condensed consolidated balance sheet as of December 31, 2014:
		31-Dec-14
	Assets:
	Cash and cash equivalents	$	4,514
	Accounts receivable		2,759
	Inventories		119
	Deferred tax assets		1,930
	Other current assets		2,492
	Property & Equipment, net		14,519
	Goodwill, net		6,491
	Other intangible assets, net		38,331
	Other assets		1,207
	Assets held for sale		72,362
	Less: Impairment		(1,507	)
	Assets held for sale, net	$	70,855
	Liabilities:
	Accounts payable	$	5,518
	Other accrued liabilities		5,933
	Deferred revenues		97
	Long term debt:		1,080
	Other liabilities		6,870
	Deferred tax liability		14,999
	Liabilities held for sale		34,497
	Total net assets of discontinued operations	$	36,358
	All such assets were disposed of, and the liabilities extinguished upon closing of the sale transaction in February 2015.

Acquisition

Acquisition	3 Months Ended
	Mar. 31, 2015
Acquisition [Abstract]
Acquisition	Note 3
	Acquisition:
	Acquisition of LCA-Vision Inc.:
	On May 12, 2014, PhotoMedex Inc., completed the acquisition of 100% of the shares of LCA-Vision, a previously publicly-traded Delaware corporation.
	LCA is a provider of fixed-site laser vision corrections services at its LasikPlus® vision centers. The vision centers provide the staff, facilities, equipment and support services for performing laser vision correction that employs advanced laser technologies to help correct nearsightedness, farsightedness and astigmatism. The vision centers are supported by independent ophthalmologists and credentialed optometrists, as well as other healthcare professionals. Substantially all of LCA's revenues are derived from the delivery of laser vision correction procedures performed in the vision centers.
	The purchase price of LCA-Vision was $106,552 in aggregate consideration, paid in cash (including the full use of the credit facility), consisting of:
	Fair value LCA-Vision stock (A)		$	103,896
	Fair value of LCA-Vision restricted stock units, including payroll taxes (B)			2,656
	Total purchase price		$	106,552
	A.	Based on 19,347,554 outstanding shares of LCA-Vision common stock at May 12, 2014.
	B.	Based on 476,436 outstanding or deemed to be outstanding restricted stock units of LCA-Vision common stock at May 12, 2014.
	The fair value of the assets acquired and liabilities assumed were based on management estimates and values derived from an outside independent appraisal. The Company expected that the allocation would be finalized within twelve months after the merger. However, LCA was sold in January 2015 and it is presented as a discontinued operations, see Note 2. Accordingly management has determined to retain the provisional amounts. Based on the purchase price allocation, the following table summarizes the provisional fair value amounts of the assets acquired and liabilities assumed at the date of acquisition:
	Cash and cash equivalents		$	29,042
	Current assets, excluding cash and cash equivalents			6,114
	Deferred tax asset, current			1,124
	Property, plant and equipment			17,269
	Identifiable intangible assets			39,050
	Other assets			1,518
	Total assets acquired at fair value			94,117
	Current liabilities			(19,009	)
	Long-term debt			(1,603	)
	Deferred tax liability, long-term			(9,138	)
	Other long-term liabilities			(7,397	)
	Total liabilities assumed			(37,147	)
	Net assets acquired		$	56,970
	The purchase price exceeded the fair value of the net assets acquired by $49,582, which was recorded as goodwill. LCA was recognized at that time as a new reportable segment and the entire goodwill was allocated to the activities of LCA.
	On January 31, 2015, the Company sold 100% of the shares of LCA-Vision Inc. for $40 million in cash. Excluding working capital adjustments and professional fees, the Company realized net proceeds of approximately $37.7 million.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventories [Abstract]
Inventories	Note 4
	Inventories:
		31-Mar-15		31-Dec-14
		(unaudited)
	Raw materials and work in progress	$	7,699	$	7,483
	Finished goods		12,164		11,897
	Total inventories	$	19,863	$	19,380
	Work-in-process is immaterial, given the Company's typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2015
Property and Equipment [Abstract]
Property and Equipment	Note 5
	Property and Equipment:
		31-Mar-15			31-Dec-14
		(unaudited)
	Lasers-in-service	$	20,725		$	18,974
	Equipment, computer hardware and software		4,902			4,870
	Furniture and fixtures		764			767
	Leasehold improvements		477			481
			26,868			25,092
	Accumulated depreciation and amortization		(12,321	)		(11,290	)
	Property and equipment, net	$	14,547		$	13,802
	Depreciation and related amortization expense was $1,052 and $824 for the three months ended March 31, 2015 and 2014, respectively.

Patents_and_Licensed_Technolog

Patents and Licensed Technologies, net	3 Months Ended
	Mar. 31, 2015
Patents and Licensed Technologies, net [Abstract]
Patents and Licensed Technologies, net	Note 6
	Patents and Licensed Technologies, net:
		31-Mar-15			31-Dec-14
		(unaudited)
	Gross Amount beginning of period	$	15,626		$	15,648
	Additions		29			168
	Translation differences		(139	)		(190	)
	Gross Amount end of period		15,516			15,626
	Accumulated amortization		(7,263	)		(6,815	)
	Patents and licensed technologies, net	$	8,253		$	8,811
	Related amortization expense was $513 and $512 for the three months ended March 31, 2015 and 2014, respectively.
	Estimated amortization expense for amortizable patents and licensed technologies assets for the future periods is as follows:
	Last nine months of 2015	$	1,544
	2016		2,021
	2017		885
	2018		908
	2019		894
	Thereafter		2,001
	Total	$	8,253

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Other Intangible Assets [Abstract]
Goodwill and Other Intangible Assets	Note 7
	Goodwill and Other Intangible Assets:
	As part of the purchase price allocation for the reverse acquisition, the Company recorded goodwill in the amount of $24,005 and definite-lived intangibles in the amount of $12,000. Goodwill reflects the value or premium of the acquisition price in excess of the fair values assigned to specific tangible and intangible assets. Goodwill has an indefinite useful life and therefore is not amortized as an expense, but is reviewed annually for impairment of its fair value to the Company. The purchase price intrinsically recognizes the benefits of the broadened depth of the management team and the addition of a sizeable direct sales force creating greater access to the physician community with branded products and technologies. Furthermore, the purchase price paid by Radiancy, Inc., a private company, includes, among other things, other benefits such as the intrinsic value of being a Nasdaq-listed issuer post-merger and now having access to capital markets and stockholder liquidity.
	Balance at January 1, 2015	$	24,048
	Translation differences		(644	)
	Balance at March 31, 2015	$	23,404
	The Company has no accumulated impairment losses of goodwill related to the continuing operations as of March 31, 2015. See Note 2 regarding impairment of goodwill allocated to the discontinued operations.
	Set forth below is a detailed listing of other definite-lived intangible assets:
		31-Mar-15									31-Dec-14
		(unaudited)
		Trademarks			Customer Relationships			Total			Trademarks			Customer Relationships			Total
	Gross Amount beginning of period	$	5,692		$	6,289		$	11,981		$	5,772		$	6,417		$	12,189
	Translation differences		(57	)		(94	)		(151	)		(80	)		(128	)		(208	)
	Gross Amount end of period		5,635			6,195			11,830			5,692			6,289			11,981
	Accumulated amortization		(1,855	)		(2,039	)		(3,894	)		(1,731	)		(1,913	)		(3,644	)
	Net Book Value	$	3,780		$	4,156		$	7,936		$	3,961		$	4,376		$	8,337
	Related amortization expense was $300 for each of the periods ended March 31, 2015 and 2014. Customer Relationships embody the value to the Company of relationships that Pre-merged PhotoMedex had formed with its customers. Trademarks include the tradenames and various trademarks associated with Pre-merged PhotoMedex products (e.g. "XTRAC", "Neova" "Omnilux" and "Lumiere").
	Estimated amortization expense for the above amortizable intangible assets for the future periods is as follows:
	Last nine months of 2015	$	900
	2016		1,200
	2017		1,200
	2018		1,200
	2019		1,200
	Thereafter		2,236
	Total	$	7,936

Accrued_Compensation_and_relat

Accrued Compensation and related expenses	3 Months Ended
	Mar. 31, 2015
Accrued Compensation and related expenses [Abstract]
Accrued Compensation and related expenses	Note 8
	Accrued Compensation and related expenses:
		31-Mar-15		31-Dec-14
		(unaudited)
	Accrued payroll and related taxes	$	620	$	513
	Accrued vacation		410		211
	Accrued commissions and bonuses		1,781		1,898
	Total accrued compensation and related expense	$	2,811	$	2,622

Other_Accrued_Liabilities

Other Accrued Liabilities	3 Months Ended
	Mar. 31, 2015
Other Accrued Liabilities [Abstract]
Other Accrued Liabilities	Note 9
	Other Accrued Liabilities:
			31-Mar-15			31-Dec-14
			(unaudited)
	Accrued warranty, current, see Note 1		$	673		$	665
	Accrued taxes, net			1,534			1,362
	Accrued sales returns (1)			5,941			7,651
	Other accrued liabilities			2,223			3,344
	Total other accrued liabilities		$	10,371		$	13,022
	-1	The activity in the accrued sales returns liability account was as follows:
			Three Months Ended March 31,
			2015			2014
			(unaudited)			(unaudited)
	Balance at beginning of year		$	7,651		$	16,046
	Additions that reduce net sales			6,519			9,899
	Deductions from reserves			(8,229	)		(16,172	)
	Balance at end of period		$	5,941		$	9,773

Longterm_Debt

Long-term Debt	3 Months Ended
	Mar. 31, 2015
Long-term Debt [Abstract]
Long-term Debt	Note 10
	Long-term Debt:
	In the following table is a summary of the Company's long-term debt:
		31-Mar-15			December 31,2014
		(unaudited)
	Senior-secured credit facilities	$	40,018		$	76,500
	Less: current portion		(3,000	)		(38,732	)
	Long-term debt	$	37,018		$	37,768
	Senior Secured Credit Facilities
	On May 12, 2014, the Company entered into an $85 million senior secured credit facilities ("the Facilities") with JP Morgan Chase ("Chase") which included a $10 million revolving credit facility and a $75 million four-year term loan. The facilities were utilized to refinance the existing term debt with Chase, fund the acquisition of LCA and for working capital and other general corporate purposes.
	Interest is determined at Eurodollar plus a margin between 3.25% and 4.50%. The margin is updated quarterly based on the then-current leverage ratio. The facilities are secured by a first priority security interest in and lien on all assets of the Company. All current and future subsidiaries are guarantors on the facilities. There are financial covenants including; a maximum leverage covenant and a minimum fixed charge covenant, which the Company was required to maintain. These covenants will be determined quarterly based on a rolling past four quarters of financial data. As of December 31, 2014 and March 31, 2015, the Company continued to fail to meet both financial covenants and is in default of the credit facilities
	On August 4, 2014, the Company received a notice of default and a reservation of rights from Chase and engaged a third-party independent advisor to assist the Company in negotiating a longer term solution to the defaults. The parties had entered into an initial Forbearance Agreement (the "Initial Forbearance Agreement") on August 25, 2014. On November 4, 2014, the Company entered into an Amended and Restated Forbearance Agreement (the "Amended Forbearance Agreement") with the lenders that are parties to the Credit Agreement and with Chase, as Administrative Agent for the Lenders.
	Effective February 28, 2015, the Company entered into a Second Amended and Restated Forbearance Agreement (the "Second Amended Forbearance Agreement") with the lenders (the "Lenders") that are parties to the Credit Agreement dated May 12, 2014, and with JP Morgan Chase, as Administrative Agent for the Lenders.
	Pursuant to the terms of the Second Amended Forbearance Agreement, the Lenders have agreed to forbear from exercising their rights and remedies with respect to the Specified Events of Default from August 25, 2014 until April 1, 2016, or earlier if an event of default occurs (the "Forbearance Period"). Chase and the Lenders agreed that the Company shall not be obligated to pay the principal amounts set forth in Section 2.08(b) of the Credit Agreement for any date identified therein during the period beginning on February 28, 2015 and ending on the end of the Forbearance Period (the "Effective Period"), and that any failure to do so shall not constitute a default or event of default. Instead, the Lenders and the Company agreed that the Company would make prepayments against the Term Loan of $250,000 on the first business day of each month during the Forbearance Period, which will be applied in direct order of maturity. The Company also agreed that, on or before the fifth calendar day of each month, the Company would pay against the Term Loan $125,000 to the extent that the cash-on-hand exceeds $5 million, and 100% of the cash-on-hand in excess of $7 million, also to be applied to the Term Loan in inverse order of maturity. For the three months ended March 31, 2015, the Company paid $36,482 of principal payments on the loan.
	Under the provisions of the Second Amended Forbearance Agreement, the Company will not have to comply with certain financial covenants contained in Section 6.11 of the Credit Agreement for the Forbearance Period, and that any failure to do so shall not constitute a default or event of default. However, the Company will have to meet certain minimum EBITDA targets (as defined in the forbearance agreement) for the quarters ending March 31, 2015, June 30, 2015, September 30, 2015 and December 31, 2015. The Company has met the EBITDA target as of March 31, 2015.
	Pursuant to the Second Amended Forbearance Agreement, all loans under the Facilities shall, beginning November 1, 2014, bear interest at the CB Floating Rate (as defined in the Credit Agreement) plus 4.00%. Additionally, following the occurrence and continuance of any default or event of default (other than a Specified Event of Default), the Company's obligations under the Facilities shall, at the option of Chase and the Lenders, bear interest at the rate of 2.00% plus the rate otherwise in effect.
	The Company and its subsidiaries have also agreed not to pay in cash any compensation to either the Company's Chief Executive Officer or President that is based on a percentage of sales or another metric other than those officer's base salary, perquisites and standard benefits provided to or on behalf of those executives under the terms of their employment agreements. Those payments may be accrued or deferred and paid in cash only after the repayment of the Facilities in full.
	The Company has agreed to provide, on or before May 29, 2015, a strategic business plan for the overall direction of the Company's and its subsidiaries' businesses, including projected income statements, balance sheets, schedules of cash receipts and cash disbursements, payments and month-end balances, and detailed notes and assumptions, projected on a monthly basis through April 1, 2016. The Company has also agreed to provide quarterly updates to that plan by August 31, 2015, November 30, 2015 and February 29, 2016.
	The Company continues to retain the services of both Getzler Henrich & Assoc. LLC, a third-party independent business advisor, as well as Canaccord Genuity, Inc., a banking and financial services company, and has also retained the services of Nomura Securities International, Inc., also a banking and financial services company. During the Forbearance Agreement, the Company and these advisors will continue to prepare and distribute offering memoranda and other marketing materials to prospective lenders with regard to a proposed credit facility for the Company, the proceeds of which would be in an amount sufficient to repay in full and in cash the Company's remaining obligations under the Facilities, and to explore other strategic alternatives. The closing of any such refinancing or alternative arrangement would occur no later than the end of the Forbearance Period.
	The Company agreed to limit certain capital expenditures to $100,000 per quarter, except for those involving the Company's XTRAC ® or VTRAC ®  medical devices, and will not make investments or acquire any other interests in affiliated companies except as agreed to by the Lenders.
	As consideration for the Lender's entry into the Second Amended Forbearance Agreement, the Company has agreed to pay the Lenders certain forbearance fees (the "Forbearance Fees"), which are payable on the last business day of each of the specified months: for May and June 2015, $750,000 each month; for July through September 2015, $1,000,000 each month; for October through December 2015, $1,250,000 each month; and for January through March 2016, $1,500,000 each month. However, should the Company complete a capital transaction acceptable to the Lenders that reduces the then-outstanding principal balance of the Term Loan to less than $10 million and repays all Forbearance Fees accrued and unpaid to that date, the monthly Forbearance Fee for the remainder of the Forbearance Period shall be earned and accrued in an amount that is 50% of the amount specified for each of the remaining months. In addition, the $500,000 Forbearance Fee set forth in Section 4.10(b) of the Amended Forbearance Agreement remains due and payable to the Lenders on the earlier of the Expiration Date or the Termination Date of the Forbearance Period. All Forbearance Fees are considered earned and are included in the Obligations under the Credit Agreement. The total Forbearance Fees are being expensed on a straight line basis over the term of the Second Amended Forbearance Agreement. For the three months ended March 31, 2015, the Company expensed $1,481 of these forbearance fees.
	The Second Amended Forbearance Agreement is also subject to customary covenants, including limitations on the incurrence of or payments on indebtedness to other persons or entities and requirements that the Company provide periodic financial information and information regarding the status of outstanding litigation involving the Company and its subsidiaries to the Lenders.
	The following table summarizes the future minimum payments that the Company expects to make for long-term debt:
	Last nine months of 2015	$	2,250
	2016		37,768
		$	40,018

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Taxes [Abstract]
Income Taxes	Note 11
	Income Taxes:
	The Company's tax expense includes federal, state and foreign income taxes at statutory rates and the effects of various permanent differences.
	The difference between the Company's effective tax rates for the three month period ended March 31, 2015 and the U.S. Federal statutory rate (34%) resulted primarily from current federal and state losses for which no tax benefit is provided due to the 100% valuation allowance for those jurisdictions. In addition, the Israeli and UK subsidiaries' earnings are taxed at rates lower than the U.S. federal statutory rate (Israel 26.5% standard corporation tax rate and in the UK 20%).
	During the three months ended March 31, 2015, the Company had no material changes to liabilities for uncertain tax positions. The Company is currently under examination for its 2012 federal return and various states. At this time, the Company does not believe that the results of these examinations will have a material impact on its financial statements.

Commitments_and_contingencies

Commitments and contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and contingencies [Abstract]
Commitments and contingencies	Note 12
	Commitments and contingencies:
	During the year ended December 31, 2013, Radiancy, Inc., a wholly-owned subsidiary of PhotoMedex, commenced legal action against Viatek Consumer Products Group, Inc., over Viatek's Pearl and Samba hair removal products which Radiancy believes infringe the intellectual property covering its no!no! hair removal devices. The first suit, which was filed in the United States Federal Court, Southern District of New York, includes claims against Viatek for patent infringement, trademark and trade dress infringement, and false and misleading advertising. A second suit against Viatek was filed in Canada, where the Pearl is offered on that country's The Shopping Channel, alleging trademark and trade dress infringement, and false and misleading advertising. Viatek's response contains a variety of counterclaims and affirmative defenses against both Radiancy and its parent company PhotoMedex, including, among other counts, claims regarding the invalidity of Radiancy's patents and antitrust allegations regarding Radiancy's conduct.
	Radiancy, and PhotoMedex, had moved to dismiss PhotoMedex from the case, and to dismiss the counterclaims and affirmative defenses asserted by Viatek. On March 28, 2014, the Court granted the Company's motion and dismissed PhotoMedex from the lawsuit. The Court also dismissed certain counterclaims and affirmative defenses asserted by Viatek, including Viatek's counterclaims against Radiancy for antitrust, unfair competition, and tortious interference with business relationships and Viatek's affirmative defenses of unclean hands and inequitable conduct before the U.S. Patent and Trademark Office in procuring its patent. Radiancy had also moved for sanctions against Viatek for failure to provide meaningful and timely responses to Radiancy's discovery requests; on April 1, 2014, the Court granted that motion. Viatek appealed both the sanctions ruling and the dismissal of Viatek's counterclaims and defenses from the case, as well as PhotoMedex dismissal as a plaintiff; the Court has denied those appeals. The Court has appointed a Special Master to oversee discovery. A Markman hearing on the patents at issue was held on March 2, 2015. Viatek has requested an opportunity to supplement its patent invalidity contentions in the US case; Radiancy opposes that request. Radiancy has been granted permission by the US Court to supplement its earlier sanctions motion to include the legal fees and costs associated with preparing and prosecuting that motion. As of March 31, 2015, discovery and related court hearings continue in both the US and the Canadian cases. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the case is still in the early stages of discovery to determine the validity of any claim or claims made by Viatek. Therefore, the Company has not recorded any reserve or contingent liability related to this particular legal matter. However, in the future, as the case progresses, the Company may be required to record a contingent liability or reserve for this matter.
	On December 20, 2013, PhotoMedex, Inc. was served with a putative class action lawsuit filed in the United States District Court for the Eastern District of Pennsylvania against the Company and its two top executives, Dolev Rafaeli, Chief Executive Officer, and Dennis M. McGrath, President and Chief Financial Officer. The suit alleges various violations of the Federal securities laws between November 7, 2012 and November 14, 2013.
	A mediation on possible settlement of this action was held on November 10, 2014; the parties including the Company's insurance carrier have agreed on a possible settlement. On March 11, 2015, the Court entered an order preliminarily approving that proposed settlement, which provides a fund of $1.5 million for the benefit of those persons or entities who purchased securities issued by the Company during the period November 6, 2012 and November 5, 2013, inclusive.  The settlement fund will also pay for plaintiffs' counsel's fees and expenses approved by the Court with respect to the action. The Company maintains insurance that will help defray the cost of the proposed settlement, and does not expect the proposed settlement to have a material impact on its financial results. The proposed settlement is subject to final approval by the Court.  A hearing has been scheduled at 9:30 a.m., on July 20, 2015 to determine whether to (i) approve the settlement, (ii) dismiss the action with prejudice, and (iii) provide for the payment of plaintiffs' counsel's attorney's fees and expenses, and consider an application for reimbursement of expenses (including lost wages) of the lead plaintiff. The Company has paid its own legal fees up to the deductible cap on its insurance policy, and all amounts to be paid to plaintiffs and plaintiff's counsel will be paid by the carrier of the insurance policy.
	The Company was served on July 29, 2014 with an application to certify a class action, filed in Israel District Court for Tel Aviv against the Company and its two top executives, Dolev Rafaeli, Chief Executive Officer, and Dennis M. McGrath, President and Chief Financial Officer. The plaintiffs' who initiated this complaint have agreed to be part of, and be bound by, the possible settlement reached in the United States District Court for the Eastern District of Pennsylvania against the Company and the same two top executives.
	There were multiple class-action lawsuits filed in connection with PhotoMedex's proposed acquisition of LCA-Vision, Inc. All cases asserted claims against LCA-Vision, Inc., and a mix of other defendants, including LCA's chief executive officer and directors, PhotoMedex, and Gatorade Acquisition Corp., a wholly owned subsidiary of PhotoMedex. The complaints generally allege that the proposed acquisition undervalued LCA and deprived LCA's shareholders of the opportunity to participate in LCA's long-term financial prospects, that the "go shop" and "deal-protection" provisions of the Merger Agreement were designed to prevent LCA from soliciting or receiving competing offers, that LCA's Board breached its fiduciary duties and failed to maximize that company's stockholder value, and that LCA, PhotoMedex, and Gatorade aided and abetted the LCA defendants' alleged breaches of duty. The parties have reached a possible settlement in these suits. On March 23, 2015, the Ohio Court entered an order preliminarily approving that proposed settlement. Under the terms of settlement, LCA had published certain additional disclosure statements regarding its acquisition by the Company and its financial statements prior to its shareholder vote on the acquisition, which was held on May 12, 2014. The settlement also provides for the proposed payment of plaintiffs' counsel's fees and expenses with respect to the action. The Company believes that LCA maintains insurance that will help defray the cost of the proposed settlement; the Company will contribute less than $100,000 to the settlement, plus the payment of its legal fees, and does not expect the proposed settlement to have a material impact on its financial results. The proposed settlement is subject to final approval by the Court. A hearing has been scheduled at 8:30 a.m., on June 19, 2015 to determine whether to approve the settlement, whether the settlement provided adequate notice to shareholders, thereafter dismiss the action with prejudice, whether the court should enter a complete bar order regarding this matter, and whether to provide for the payment of plaintiffs' counsel's attorney's fees and expenses.
	On April 25, 2014, a putative class action lawsuit was filed in the United States District Court for the District of Columbia against the Company's subsidiary, Radiancy, Inc. and Dolev Rafaeli, Radiancy's President. The suit was filed by Jan Mouzon and twelve other customers residing in ten different states who purchased Radiancy's no!no! Hair products. It alleges various violations of state business and consumer protection codes including false and misleading advertising, unfair trade practices, and breach of express and implied warranties. The complaint seeks certification of the putative class, or, alternatively, certification as subclasses of plaintiffs residing in those specific states. The complaint also seeks an unspecified amount of monetary damages, pre-and post-judgment interest and attorneys' fees, expert witness fees and other costs. Dr. Rafaeli was served with the Complaint on May 5, 2014; to date, Radiancy, has not been served. A mediation was scheduled in this matter for November 24, 2014, but no settlement was reached. On March 30, 2015, the Court dismissed this action in its entirety for failure to state a claim. The Court specifically dismissed with prejudice the claims pursuant to New York General Business Law §§349-50 and the implied warranty of fitness for a particular purpose; the other counts against Radiancy were dismissed without prejudice. The Court also granted Dr. Rafaeli's motion to dismiss the actions against him for lack of personal jurisdiction over him by the Court. The Court denied the plaintiffs request for jurisdictional discovery with respect to Dr. Rafaeli and plaintiffs request to amend the complaint. Radiancy and its officers intend to continue to vigorously defend themselves against any attempts to continue this lawsuit. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the case has only been initiated and no discovery has been conducted to determine the validity of any claim or claims made by plaintiffs. Therefore, the Company has not recorded any reserve or contingent liability related to these particular legal matters. However, in the future, as the cases progress, the Company may be required to record a contingent liability or reserve for these matters.
	On June 30, 2014, the Company's subsidiary, Radiancy, Inc., was served with a class action lawsuit filed in the Superior Court in the State of California, County of Kern. The suit was filed by April Cantley, who purchased Radiancy's no!no! Hair products. It alleges various violations of state business and consumer protection codes including false and misleading advertising, breach of express and implied warranties and breach of the California Legal Remedies Act. The complaint seeks certification of the class, which consists of customers in the State of California who purchased the no!no! Hair devices. The complaint also seeks an unspecified amount of monetary damages, pre-and post-judgment interest and attorneys' fees, expert witness fees and other costs. Radiancy has filed an Answer to this Complaint; the case is now in the discovery phase. Radiancy and its officers intend to vigorously defend themselves against this lawsuit. Discovery has now commenced in this action. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the case has only been initiated and no discovery has been conducted to determine the validity of any claim or claims made by plaintiffs. Therefore, the Company has not recorded any reserve or contingent liability related to these particular legal matters. However, in the future, as the cases progress, the Company may be required to record a contingent liability or reserve for these matters.
	From time to time in the ordinary course of our business, we and certain of our subsidiaries are involved in certain other legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, and claims regarding false advertising and product efficacy which were already raised and reviewed in the Tria litigation. We believe, based on discussions with legal counsel, that these other litigations and claims will likely be resolved without a material effect on our consolidated financial position, results of operations or liquidity. However, litigation is inherently unpredictable, and excessive verdicts can result from litigation. Although we believe we have substantial defenses in these matters, we may, in the future, incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in a particular period.

Employee_Stock_Benefit_Plans

Employee Stock Benefit Plans	3 Months Ended
	Mar. 31, 2015
Employee Stock Benefit Plans [Abstract]
Employee Stock Benefit Plans	Note 13
	Employee Stock Benefit Plans:
	Post-Reverse Merger
	The Company has a Non-Employee Director Stock Option Plan. This plan has authorized 370,000 shares; of which 7,000 shares had been issued or were reserved for issuance as awards of shares of common stock, and 12,912 shares were reserved for outstanding stock options. The directors, who were elected to our Board in connection with the reverse merger, each received a one-time stock award of 5,000 shares of the Company's common stock in January 2012.
	In addition, the Company has a 2005 Equity Compensation Plan ("2005 Equity Plan"). The 2005 Equity Plan has authorized 6,000,000 shares, of which 3,071,095 shares had been issued or were reserved for issuance as awards of shares of common stock, and 966,526 shares were reserved for outstanding options as of March 31, 2015.
	Stock option activity under all of the Company's share-based compensation plans for the three months ended March 31, 2015 was as follows:
		Number of Options			Weighted Average Exercise Price
	Outstanding, January 1, 2015		1,159,554		$	16.23
	Granted		-			-
	Exercised		-			-
	Cancelled		(180,116	)		15.39
	Outstanding, March 31, 2015		979,438		$	16.38
	Options exercisable at March 31, 2015		626,138		$	16.23
	At March 31, 2015, there was $7,260 of total unrecognized compensation cost related to non-vested option grants and stock awards that is expected to be recognized over a weighted-average period of 3.4 years. The intrinsic value of options outstanding and exercisable at March 31, 2015 was not significant.
	The Company calculates expected volatility for share-based grants based on historic daily stock price observations of its common stock. For estimating the expected term of share-based grants made in the three months ended March 31, 2015, the Company has adopted the simplified method. The Company has used historical data to estimate expected employee behaviors related to option exercises and forfeitures and included these expected forfeitures as a part of the estimate of expense as of the grant date.
	The Company uses the Black-Scholes option-pricing model to estimate fair value of grants of stock options. With respect to grants of options, the risk-free rate of interest is based on the U.S. Treasury rates appropriate for the expected term of the grant or award.
	On February 26, 2015, the Company issued 1,495,000 restricted stock units to a number of employees. The restricted shares have a purchase price of $0.01 per share and vest, and cease to be subject to the Company's right of repurchase, over a four-year period. The Company determined the fair value of the awards to be the quoted market price of the Company's common stock units on the date of issuance less the value paid for the award. The aggregate fair value of these restricted stock units issued was $2,766.
	Total stock based compensation expense was $3,337, including $2,363 that is included in discontinued operations, and $1,262 for the three months ended March 31, 2015 and 2014, including amounts relating to consultants.

Business_Segments_and_Geograph

Business Segments and Geographic Data	3 Months Ended
	Mar. 31, 2015
Business Segments and Geographic Data [Abstract]
Business Segments and Geographic Data	Note 14
	Business Segments and Geographic Data:
	The Company organized its business into three operating segments to better align its organization based upon the Company's management structure, products and services offered, markets served and types of customers, as follows: The Consumer segment derives its revenues from the design, development, manufacturing and selling of long-term hair reduction and acne consumer products. The Physician Recurring segment derives its revenues from the XTRAC procedures performed by dermatologists, the sales of skincare products, the sales of surgical disposables and accessories to hospitals and surgery centers and on the repair, maintenance and replacement parts on our various products. The Professional segment generates revenues from the sale of equipment, such as lasers, medical and esthetic light and heat-based products and LED products. Management reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance. For a period during 2014 through January 31, 2015 the Company had a fourth operating segment, Clinics segment. This represented our LCA business which is classified as discontinued operations as of December 31, 2014. See also Note 2, Discontinued Operations.
	Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other financing income (expense), net is also not allocated to the operating segments. Unallocated assets include cash and cash equivalents, prepaid expenses and deposits.
	The following tables reflect results of operations from our business segments for the periods indicated below:
	Three Months Ended March 31, 2015 (unaudited)
		CONSUMER			PHYSICIAN RECURRING			PROFESSIONAL			TOTAL
	Revenues	$	18,129		$	7,558		$	2,462		$	28,149
	Costs of revenues		3,497			2,777			1,648			7,922
	Gross profit		14,632			4,781			814			20,227
	Gross profit %		80.7	%		63.3	%		33.1	%		71.9	%
	Allocated operating expenses:
	Engineering and product development		338			321			96			755
	Selling and marketing expenses		14,719			5,191			222			20,132
	Unallocated operating expenses		-			-			-			4,729
			15,057			5,512			318			25,616
	Income (loss) from continuing operations		(425	)		(731	)		496			(5,389	)
	Interest  and other financing expense, net		-			-			-			(2,551	)
	Income (loss) from continuing operations before taxes	$	(425	)	$	(731	)	$	496		$	(7,940	)
	Three Months Ended March 31, 2014 (unaudited)
		CONSUMER			PHYSICIAN RECURRING			PROFESSIONAL			TOTAL
	Revenues	$	40,870		$	7,219		$	1,986		$	50,075
	Costs of revenues		6,250			2,830			1,265			10,345
	Gross profit		34,620			4,389			721			39,730
	Gross profit %		84.7	%		60.8	%		36.3	%		79.3	%
	Allocated operating expenses:
	Engineering and product development		287			310			198			795
	Selling and marketing expenses		27,157			4,011			457			31,625
	Unallocated operating expenses		-			-			-			7,587
			27,444			4,321			655			40,007
	Income (loss) from operations		7,176			68			66			(277	)
	Interest and other financing income, net		-			-			-			(147	)
	Income (loss) before taxes	$	7,176		$	68		$	66		$	(424	)
	For the three months ended March 31, 2015 and 2014, net revenues by geographic area (determined by ship to location) were as follows:
		Three Months Ended
		March 31,
		2015			2014
		(unaudited)			(unaudited)
	North America 1	$	20,764		$	39,972
	Asia Pacific 2		2,371			2,377
	Europe (including Israel)		4,899			7,408
	South America		115			318
		$	28,149		$	50,075
	1 United States	$	18,678		$	34,766
	1 Canada	$	2,062		$	5,206
	2  Japan	$	91		$	698
	As of March 31, 2015 and December 31, 2014, long-lived assets by geographic area were as follows:
		31-Mar-15			31-Dec-14
		(unaudited)
	North America	$	13,169		$	12,385
	Asia Pacific		310			286
	Europe (including Israel)		1,065			1,127
	South America		3			4
		$	14,547		$	13,802
	The Company discusses segmental details in its Management Discussion and Analysis found elsewhere in this Quarterly Report on Form 10-Q.

Significant_Customer_Concentra

Significant Customer Concentration	3 Months Ended
	Mar. 31, 2015
Significant Customer Concentration [Abstract]
Significant Customer Concentration	Note 15
	Significant Customer Concentration:
	No single customer accounted for more than 10% of total company revenues for either of the three months ended March 31, 2015 or 2014.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 16
	Subsequent Events:
	In April 2015, the Company signed an exclusive distribution agreement, by its Radiancy Inc. subsidiary, with Synergy Trading Corporation for certain no!no!™ products in Japan. This agreement includes Radiancy's no!no! 8800 and no!no! PRO. In addition, Synergy will launch two new no!no! models during 2016 and has a right of first refusal to market additional Radiancy consumer products. The agreement runs through December 31, 2016 and is renewable thereafter. Synergy placed an initial stocking order of $1.2 million for immediate shipment.
	The Company entered into a Third Amendment to Standard Industrial/commercial Multi-Tenant Lease-Net, effective April 30, 2015, for our manufacturing facility located in Carlsbad, California. The Amendment extends the lease for that facility an additional twenty-four months; the lease now expires on September 30, 2017. Monthly base rent for the facility for the period October 1, 2015-September 30, 2016 is set at $16,227; that monthly base rent increases to $16,714 for the succeeding twelve months. The Base Rent includes a one-time Lessee Improvement Allowance up to $42,000 to perform certain improvements to the facility. The lease also requires the Company to pay its proportionate share of certain expenses, including real property taxes, real property insurance and common area maintenance charges.

The_Company_Policies

The Company (Policies)	3 Months Ended
	Mar. 31, 2015
The Company [Abstract]
Accounting Principles	Accounting Principles
	The accompanying condensed consolidated financial statements and related notes should be read in conjunction with our consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 ("fiscal 2014"). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company's financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.
	The results for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015 or for any other interim period or for any future period.
Principles of Consolidation	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and the wholly- and majority-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Held for Sale classification and Discontinued Operations	Held for Sale Classification and Discontinued Operations
	A disposal group is reported as held for sale when management has approved or received approval to sell and is committed to a formal plan, the disposal group is available for immediate sale, the business is being actively marketed, the sale is anticipated to occur during the next 12 months and certain other specified criteria are met. A disposal group classified as held for sale is recorded at the lower of its carrying amount or estimated fair value less cost to sell. If the carrying value of the business exceeds its estimated fair value less cost to sell, a loss is recognized. However, when disposal group meets the held for sale criteria, the Company, first evaluates whether the carrying amounts of the assets not covered by ASC 360-10 included in the disposal group (such as goodwill) are required to be adjusted in accordance with other applicable GAAP before measuring the disposal group at fair value less cost to sell.
	Assets and liabilities related to a disposal group classified as held for sale are segregated in the consolidated balance sheet in the period in which the business is classified as held for sale.
	Operations of a disposal group are reported as discontinued operations if the disposal group is classified as held for sale, the operations and cash flows of the business have been or will be eliminated from our ongoing operations as a result of a disposal transaction and we will not have any significant continuing involvement in the operations of the business after the disposal transaction. See below regarding change to the criteria for reporting discontinued operations.
	The results of discontinued operations are reported in discontinued operations in the consolidated statement of operations for current and prior periods commencing in the period in which the business meets the criteria of a discontinued operation, and include any gain or loss recognized on closing or adjustment of the carrying amount to fair value less cost to sell. Depreciation is not recorded on assets of a business while it is classified as held for sale.
	At December 31, 2014, held for sale assets and liabilities consisted of the LCA operating segment, and its results of operations were presented as discontinued operations in the consolidated statement of operations in the periods ended December 31, 2014 and March 31, 2015 (see also Note 2 Discontinued Operations).
Revenue Recognition	Revenue Recognition
	The Company recognizes revenues from product sales when the following four criteria have been met: (i) the product has been delivered and the Company has no significant remaining obligations; (ii) persuasive evidence of an arrangement exists; (iii) the price to the buyer is fixed or determinable; and (iv) collection is reasonably assured. Revenues from product sales are recorded net of provisions for estimated chargebacks, rebates, expected returns and cash discounts.
	The Company ships most of its products FOB shipping point, although from time to time certain customers, for example governmental customers, will be granted FOB destination terms. Among the factors the Company takes into account when determining the proper time at which to recognize revenue are (i) when title to the goods transfers and (ii) when the risk of loss transfers. Shipments to distributors or physicians that do not fully satisfy the collection criteria are recognized when invoiced amounts are fully paid or fully assured and included in deferred revenues until that time.
	For revenue arrangements with multiple deliverables within a single, contractually binding arrangement (usually sales of products with separately priced extended warranty), each element of the contract is accounted for as a separate unit of accounting when it provides the customer value on a stand-alone basis and there is objective evidence of the fair value of the related unit.
	With respect to sales arrangements under which the buyer has a right to return the related product, revenue is recognized only if all the following conditions are met: the price is fixed or determinable at the date of sale; the buyer has paid, or is obligated to pay and the obligation is not contingent on resale of the product; the buyer's obligation would not be changed in the event of theft or physical destruction or damage of the product; the buyer has economic substance; the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer; and the amount of future returns can be reasonably estimated.
	The Company provides a provision for product returns based on the experience with historical sales returns, in accordance with ASC Topic 605-15 with respect to sales of product when a right of return exists. Reported revenues are shown net of the returns provision. Such allowance for sales returns is included in Other Accrued Liabilities. (See Note 9).
	Deferred revenue includes amounts received with respect to extended warranty maintenance, repairs and other billable services and amounts not yet recognized as revenues. Revenues with respect to such activities are deferred and recognized on a straight-line basis over the duration of the warranty period, the service period or when service is provided, as applicable to each service.
	The Company has two distribution channels for its phototherapy treatment equipment. The Company either (i) sells its lasers through a distributor or directly to a physician or (ii) places its lasers in a physician's office (at no charge to the physician) and generally charges the physician a fee for an agreed upon number of treatments. In some cases, the Company and the customer stipulate to a quarterly or other periodic target of procedures to be performed, and accordingly revenue is recognized ratably over the period.
	When the Company places a laser in a physician's office, it generally recognizes service revenue based on the number of patient treatments performed, or purchased under a periodic commitment, by the physician. Amounts collected with respect to treatments to be performed through laser-access codes that are sold to physicians free of a periodic commitment, but not yet used, are deferred and recognized as a liability until the physician performs the treatment. Unused treatments remain an obligation of the Company because the treatments can only be performed on Company-owned equipment. Once the treatments are performed, this obligation has been satisfied.
	The Company defers substantially all revenue from sales of treatment codes ordered by and performed to its customers within the last two weeks of the period in determining the amount of procedures performed by its physician-customers. Management believes this approach closely approximates the actual amount of unused treatments that existed at the end of a period.
Functional Currency	Functional Currency
	The currency of the primary economic environment in which the operations of the Company, its U.S. subsidiaries and Radiancy Ltd., its subsidiary in Israel, are conducted is the US dollar ("$" or "dollars"). Thus, the functional currency of the Company and its subsidiaries (other than the foreign subsidiaries mentioned below) is the dollar (which is also the reporting currency of the Group). The operations of the other foreign subsidiaries are each conducted in the local currency of the subsidiary. These currencies include: Great Britain Pounds (GBP), Brazilian Real (BRL), Hong Kong Dollar (HKD), Columbian Peso (COP), South Korean Won (KRW) and Indian Rupee (INR). Substantially all of the Group's revenues are derived in dollars or in other currencies linked to the dollar. Purchases of most materials and components are carried out in, or linked to the dollar.
	Balances denominated in, or linked to, foreign currencies are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the statement of comprehensive income (loss), the exchange rates applicable to the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses.
	Assets and liabilities of foreign subsidiaries, whose functional currency is their local currency, are translated from their respective functional currency to U.S. dollars at the balance sheet date exchange rates. Income and expense items are translated at the average rates of exchange prevailing during the year. Translation adjustments are reflected in the consolidated balance sheets as a component of accumulated other comprehensive income (loss). Deferred taxes are not provided on translation adjustments as the earnings of the subsidiaries are considered to be permanently reinvested.
Fair Value Measurements	Fair Value Measurements
	The Company measures and discloses fair value in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification 820, Fair Value Measurements and Disclosures ("ASC Topic 820"). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
		•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
		•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
		•	Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors
	This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.
	The fair value of cash and cash equivalents and short term bank deposits are based on its demand value, which is equal to its carrying value. The estimated fair values of notes payable and long term debt which are based on borrowing rates that are available to the Company for loans with similar terms, collateral and maturity approximate the carrying values. Additionally, the carrying value of all other monetary assets and liabilities is estimated to be equal to their fair value due to the short-term nature of these instruments.
	Derivative financial instruments are measured at fair value, on a recurring basis. The fair value of derivatives generally reflects the estimated amounts that the Group would receive or pay to terminate the contracts at the reporting dates, based on the prevailing currency prices and the relevant interest rates. Such measurement is classified within Level 2.
	In addition to items that are measured at fair value on a recurring basis, there are also assets and liabilities that are measured at fair value on a nonrecurring basis. Assets and liabilities that are measured at fair value on a nonrecurring basis include certain long-lived assets, including goodwill. As such, we have determined that each of these fair value measurements reside within Level 3 of the fair value hierarchy.
Derivatives	Derivatives
	The Company applies the provisions of Accounting Standards Codification ("ASC") Topic 815, Derivatives and Hedging. In accordance with ASC Topic 815, all the derivative financial instruments are recognized as either financial assets or financial liabilities on the balance sheet at fair value. The accounting for changes in the fair value of a derivative financial instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For derivative financial instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation.
	From time to time the Company carries out transactions involving foreign exchange derivative financial instruments (mainly forward exchange contracts) which are expected to be paid with respect to forecasted expenses of the Israeli subsidiary (Radiancy) denominated in Israeli local currency (NIS) which is different than its functional currency.
	Such derivatives were not designated as hedging instruments, and accordingly they were recognized in the balance sheet at their fair value, with changes in the fair value carried to the Statement of Comprehensive Income (Loss) and included in interest and other financing expenses, net.
	At March 31, 2015, the balance of such derivative instruments amounted to approximately $468 in assets and approximately $206 were recognized as financing income in the Statement of Comprehensive (Loss) Income during the quarter ended that date.
	The nominal amounts of foreign currency derivatives as of March 31, 2015 consist of forward transactions for the exchange of $7,200 into NIS as of March 31, 2015.
Accrued Warranty Costs	Accrued Warranty Costs
	The Company offers a standard warranty on product sales generally for a one to two-year period. In the case of domestic sales of XTRAC lasers, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold. Total accrued warranty is included in Other Accrued Liabilities on the balance sheet. The activity in the warranty accrual during the three months ended March 31, 2015 and 2014 is summarized as follows:
			March 31,
			2015			2014
			(unaudited)			(unaudited)
	Accrual at beginning of year		$	761		$	1,151
	Additions charged to warranty expense			271			256
	Expiring warranties			(102	)		(69	)
	Claims satisfied			(116	)		(247	)
	Total			814			1,091
	Less: current portion			(673	)		(1,021	)
	Accrued extended warranty		$	141		$	70
	For extended warranty on the consumer products, see Revenue Recognition above.
Earnings Per Share	Earnings Per Share
	Basic and diluted earnings per common share were calculated using the following weighted-average shares outstanding:
			For the Three Months Ended March 31,
			2014			2014
	Weighted-average number of common and common equivalent shares outstanding:
	Basic number of common shares outstanding			19,794,210			18,719,419
	Dilutive effect of stock options and warrants			-			-
	Diluted number of common and common stock equivalent shares outstanding			19,794,210			18,719,419
	Diluted earnings per share for the three months ended March 31, 2015, exclude the impact of common stock options and warrants, totaling 3,563,503 shares, as the effect of their inclusion would be anti-dilutive, due to the net loss for the period. Diluted earnings per share for the three months ended March 31, 2014, excluded the impact of common stock options and warrants, totaling 2,444,016 shares, as the effect of their inclusion would be anti-dilutive, due to the net loss for the period.
Adoption of New Accounting Standards	Adoption of New Accounting Standards
	In April 2014, the FASB issued Accounting Standard Update 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity ("ASU 2014-08").
	The amendments in ASU 2014-08 change the criteria for reporting discontinued operations while enhancing disclosures in this area. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization's operations and financial results. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations.
	The provisions of ASU 2014-08 were required to be applied in a prospective manner to disposals or classifications as held for sale components of an entity that occur with annual periods beginning on or after December 15, 2014 and interim periods within those years.
	The company applied the provisions of ASU 2014-08 in the first quarter of 2015.
	The adoption of ASU 2014-08 did not have a material impact on the Company's consolidated results of operations and financial condition and also did not affect disposals or classifications as held for sale, of components (such as the sale of LCA) that occurred before the provisions of ASU 2014-08 became effective.
Recently Issued Accounting Standards	Recently Issued Accounting Standards
	In May 2014, The FASB issued Accounting Standard Update 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09").
	ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.
	An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures.
	For a public entity, the amendments in ASU 2014-09 are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early application is not permitted. The Company is in the process of assessing the impact, if any, of ASU 2014-09 on its consolidated financial statements.
	In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 provide guidance on management's responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 also provide guidance related to the required disclosures as a result of management evaluation. The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.

The_Company_Tables

The Company (Tables)	3 Months Ended
	Mar. 31, 2015
The Company [Abstract]
Activity in the Warranty Accrual	The activity in the warranty accrual during the three months ended March 31, 2015 and 2014 is summarized as follows:
		March 31,
		2015			2014
		(unaudited)			(unaudited)
	Accrual at beginning of year	$	761		$	1,151
	Additions charged to warranty expense		271			256
	Expiring warranties		(102	)		(69	)
	Claims satisfied		(116	)		(247	)
	Total		814			1,091
	Less: current portion		(673	)		(1,021	)
	Accrued extended warranty	$	141		$	70
Calculation of Basic and Diluted Earnings per Common Share	Basic and diluted earnings per common share were calculated using the following weighted-average shares outstanding:
		For the Three Months Ended March 31,
		2014			2014
	Weighted-average number of common and common equivalent shares outstanding:
	Basic number of common shares outstanding		19,794,210			18,719,419
	Dilutive effect of stock options and warrants		-			-
	Diluted number of common and common stock equivalent shares outstanding		19,794,210			18,719,419

Discontinued_Operations_Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2015
Discontinued Operations [Abstract]
Summary of assets and liabilities held for sale in the consolidated balance sheet	The following is a summary of assets and liabilities held for sale in the condensed consolidated balance sheet as of December 31, 2014:
		31-Dec-14
	Assets:
	Cash and cash equivalents	$	4,514
	Accounts receivable		2,759
	Inventories		119
	Deferred tax assets		1,930
	Other current assets		2,492
	Property & Equipment, net		14,519
	Goodwill, net		6,491
	Other intangible assets, net		38,331
	Other assets		1,207
	Assets held for sale		72,362
	Less: Impairment		(1,507	)
	Assets held for sale, net	$	70,855
	Liabilities:
	Accounts payable	$	5,518
	Other accrued liabilities		5,933
	Deferred revenues		97
	Long term debt:		1,080
	Other liabilities		6,870
	Deferred tax liability		14,999
	Liabilities held for sale		34,497
	Total net assets of discontinued operations	$	36,358

Acquisition_Tables

Acquisition (Tables)	3 Months Ended
	Mar. 31, 2015
Acquisition [Abstract]
Purchase Price Allocation	The purchase price of LCA-Vision was $106,552 in aggregate consideration, paid in cash (including the full use of the credit facility), consisting of:
	Fair value LCA-Vision stock (A)		$	103,896
	Fair value of LCA-Vision restricted stock units, including payroll taxes (B)			2,656
	Total purchase price		$	106,552
	A.	Based on 19,347,554 outstanding shares of LCA-Vision common stock at May 12, 2014.
	B.	Based on 476,436 outstanding or deemed to be outstanding restricted stock units of LCA-Vision common stock at May 12, 2014.
Schedule of Aggregate Consideration Paid	Based on the purchase price allocation, the following table summarizes the provisional fair value amounts of the assets acquired and liabilities assumed at the date of acquisition:
	Cash and cash equivalents		$	29,042
	Current assets, excluding cash and cash equivalents			6,114
	Deferred tax asset, current			1,124
	Property, plant and equipment			17,269
	Identifiable intangible assets			39,050
	Other assets			1,518
	Total assets acquired at fair value			94,117
	Current liabilities			(19,009	)
	Long-term debt			(1,603	)
	Deferred tax liability, long-term			(9,138	)
	Other long-term liabilities			(7,397	)
	Total liabilities assumed			(37,147	)
	Net assets acquired		$	56,970

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Inventories [Abstract]
Schedule of inventories		31-Mar-15		31-Dec-14
		(unaudited)
	Raw materials and work in progress	$	7,699	$	7,483
	Finished goods		12,164		11,897
	Total inventories	$	19,863	$	19,380

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property and Equipment [Abstract]
Schedule of property and equipment		31-Mar-15			31-Dec-14
		(unaudited)
	Lasers-in-service	$	20,725		$	18,974
	Equipment, computer hardware and software		4,902			4,870
	Furniture and fixtures		764			767
	Leasehold improvements		477			481
			26,868			25,092
	Accumulated depreciation and amortization		(12,321	)		(11,290	)
	Property and equipment, net	$	14,547		$	13,802

Patents_and_Licensed_Technolog1

Patents and Licensed Technologies, net (Tables)	3 Months Ended
	Mar. 31, 2015
Patents and Licensed Technologies, net [Abstract]
Patents and Licensed Technologies	Patents and Licensed Technologies, net:
		31-Mar-15			31-Dec-14
		(unaudited)
	Gross Amount beginning of period	$	15,626		$	15,648
	Additions		29			168
	Translation differences		(139	)		(190	)
	Gross Amount end of period		15,516			15,626
	Accumulated amortization		(7,263	)		(6,815	)
	Patents and licensed technologies, net	$	8,253		$	8,811
Amortization Expense for Amortizable Patents and Licensed Technologies	Estimated amortization expense for amortizable patents and licensed technologies assets for the future periods is as follows:
	Last nine months of 2015	$	1,544
	2016		2,021
	2017		885
	2018		908
	2019		894
	Thereafter		2,001
	Total	$	8,253

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Other Intangible Assets [Abstract]
Goodwill Acquired	Furthermore, the purchase price paid by Radiancy, Inc., a private company, includes, among other things, other benefits such as the intrinsic value of being a Nasdaq-listed issuer post-merger and now having access to capital markets and stockholder liquidity.
	Balance at January 1, 2015	$	24,048
	Translation differences		(644	)
	Balance at March 31, 2015	$	23,404
Other Definite-lived Intangible Assets	Set forth below is a detailed listing of other definite-lived intangible assets:
		31-Mar-15									31-Dec-14
		(unaudited)
		Trademarks			Customer Relationships			Total			Trademarks			Customer Relationships			Total
	Gross Amount beginning of period	$	5,692		$	6,289		$	11,981		$	5,772		$	6,417		$	12,189
	Translation differences		(57	)		(94	)		(151	)		(80	)		(128	)		(208	)
	Gross Amount end of period		5,635			6,195			11,830			5,692			6,289			11,981
	Accumulated amortization		(1,855	)		(2,039	)		(3,894	)		(1,731	)		(1,913	)		(3,644	)
	Net Book Value	$	3,780		$	4,156		$	7,936		$	3,961		$	4,376		$	8,337
Estimated Amortization Expense for Amortizable Intangible Assets	Estimated amortization expense for the above amortizable intangible assets for the future periods is as follows:
	Last nine months of 2015	$	900
	2016		1,200
	2017		1,200
	2018		1,200
	2019		1,200
	Thereafter		2,236
	Total	$	7,936

Accrued_Compensation_and_relat1

Accrued Compensation and related expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Accrued Compensation and related expenses [Abstract]
Accrued Compensation and Related Expenses		31-Mar-15		31-Dec-14
		(unaudited)
	Accrued payroll and related taxes	$	620	$	513
	Accrued vacation		410		211
	Accrued commissions and bonuses		1,781		1,898
	Total accrued compensation and related expense	$	2,811	$	2,622

Other_Accrued_Liabilities_Tabl

Other Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Other Accrued Liabilities [Abstract]
Other Accrued Liabilities			31-Mar-15			31-Dec-14
			(unaudited)
	Accrued warranty, current, see Note 1		$	673		$	665
	Accrued taxes, net			1,534			1,362
	Accrued sales returns (1)			5,941			7,651
	Other accrued liabilities			2,223			3,344
	Total other accrued liabilities		$	10,371		$	13,022
	-1	The activity in the accrued sales returns liability account was as follows:
			Three Months Ended March 31,
			2015			2014
			(unaudited)			(unaudited)
	Balance at beginning of year		$	7,651		$	16,046
	Additions that reduce net sales			6,519			9,899
	Deductions from reserves			(8,229	)		(16,172	)
	Balance at end of period		$	5,941		$	9,773

Longterm_Debt_Tables

Long-term Debt (Tables)	3 Months Ended
	Mar. 31, 2015
Long-term Debt [Abstract]
Schedule of Long-term Debt	In the following table is a summary of the Company's long-term debt:
		31-Mar-15			December 31,2014
		(unaudited)
	Senior-secured credit facilities	$	40,018		$	76,500
	Less: current portion		(3,000	)		(38,732	)
	Long-term debt	$	37,018		$	37,768
Maturities of Long-term Debt	The following table summarizes the future minimum payments that the Company expects to make for long-term debt:
	Last nine months of 2015	$	2,250
	2016		37,768
		$	40,018

Employee_Stock_Benefit_Plans_T

Employee Stock Benefit Plans (Tables)	3 Months Ended
	Mar. 31, 2015
Employee Stock Benefit Plans [Abstract]
Stock Option Activity	Stock option activity under all of the Company's share-based compensation plans for the three months ended March 31, 2015 was as follows:
		Number of Options			Weighted Average Exercise Price
	Outstanding, January 1, 2015		1,159,554		$	16.23
	Granted		-			-
	Exercised		-			-
	Cancelled		(180,116	)		15.39
	Outstanding, March 31, 2015		979,438		$	16.38
	Options exercisable at March 31, 2015		626,138		$	16.23

Business_Segments_and_Geograph1

Business Segments and Geographic Data (Tables)	3 Months Ended
	Mar. 31, 2015
Business Segments and Geographic Data [Abstract]
Results of Operations from Business Segments	The following tables reflect results of operations from our business segments for the periods indicated below:
	Three Months Ended March 31, 2015 (unaudited)
		CONSUMER			PHYSICIAN RECURRING			PROFESSIONAL			TOTAL
	Revenues	$	18,129		$	7,558		$	2,462		$	28,149
	Costs of revenues		3,497			2,777			1,648			7,922
	Gross profit		14,632			4,781			814			20,227
	Gross profit %		80.7	%		63.3	%		33.1	%		71.9	%
	Allocated operating expenses:
	Engineering and product development		338			321			96			755
	Selling and marketing expenses		14,719			5,191			222			20,132
	Unallocated operating expenses		-			-			-			4,729
			15,057			5,512			318			25,616
	Income (loss) from continuing operations		(425	)		(731	)		496			(5,389	)
	Interest  and other financing expense, net		-			-			-			(2,551	)
	Income (loss) from continuing operations before taxes	$	(425	)	$	(731	)	$	496		$	(7,940	)
	Three Months Ended March 31, 2014 (unaudited)
		CONSUMER			PHYSICIAN RECURRING			PROFESSIONAL			TOTAL
	Revenues	$	40,870		$	7,219		$	1,986		$	50,075
	Costs of revenues		6,250			2,830			1,265			10,345
	Gross profit		34,620			4,389			721			39,730
	Gross profit %		84.7	%		60.8	%		36.3	%		79.3	%
	Allocated operating expenses:
	Engineering and product development		287			310			198			795
	Selling and marketing expenses		27,157			4,011			457			31,625
	Unallocated operating expenses		-			-			-			7,587
			27,444			4,321			655			40,007
	Income (loss) from operations		7,176			68			66			(277	)
	Interest and other financing income, net		-			-			-			(147	)
	Income (loss) before taxes	$	7,176		$	68		$	66		$	(424	)
Net Revenues and Long-Lived Assets by Geographical Area	For the three months ended March 31, 2015 and 2014, net revenues by geographic area (determined by ship to location) were as follows:
		Three Months Ended
		March 31,
		2015			2014
		(unaudited)			(unaudited)
	North America 1	$	20,764		$	39,972
	Asia Pacific 2		2,371			2,377
	Europe (including Israel)		4,899			7,408
	South America		115			318
		$	28,149		$	50,075
	1 United States	$	18,678		$	34,766
	1 Canada	$	2,062		$	5,206
	2  Japan	$	91		$	698
	As of March 31, 2015 and December 31, 2014, long-lived assets by geographic area were as follows:
		31-Mar-15			31-Dec-14
		(unaudited)
	North America	$	13,169		$	12,385
	Asia Pacific		310			286
	Europe (including Israel)		1,065			1,127
	South America		3			4
		$	14,547		$	13,802

The_Company_Details

The Company (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Jan. 31, 2015
	Channel
Revenue Recognition [Abstract]
Number of distribution channels	2
Period of sales deferred	14 days
Derivatives [Abstract]
Balance of derivative instruments	$468,000
Amount recognized as financing income	206,000
Notional amounts of foreign currency derivatives	7,200,000
Activity in warranty accrual [Roll Forward]
Accrual at beginning of year	761,000	1,151,000
Additions charged to warranty expense	271,000	256,000
Expiring warranties	-102,000	-69,000
Claims satisfied	-116,000	-247,000
Total	814,000	1,091,000
Less: current portion	-673,000	-1,021,000	-665,000
Accrued extended warranty	141,000	70,000
Weighted-average number of common and common equivalent shares outstanding [Abstract]
Basic number of common shares outstanding (in shares)	19,794,210	18,719,419
Dilutive effect of stock options and warrants (in shares)	0	0
Diluted number of common and common stock equivalent shares outstanding (in shares)	19,794,210	18,719,419
Common stock options and warrants excluded from computation of diluted earnings per share (in shares)	3,563,503	2,444,016
Fee Payment Each Month For May and June 2015 [Member]
Business Acquisition [Line Items]
Lenders fee	750,000
Fee Payment Each Month For July Through September 2015 [Member]
Business Acquisition [Line Items]
Lenders fee	1,000,000
Fee Payment Each Month For October Through December 2015 [Member]
Business Acquisition [Line Items]
Lenders fee	1,250,000
Fee Payment Each Month For January Through March 2016 [Member]
Business Acquisition [Line Items]
Lenders fee	1,500,000
Senior-Secured Credit Facilities [Member]
Business Acquisition [Line Items]
Maximum borrowing capacity	85,000,000
Revolving Credit Facility [Member]
Business Acquisition [Line Items]
Maximum borrowing capacity	10,000,000
Term Loan [Member]
Business Acquisition [Line Items]
Maximum borrowing capacity	75,000,000
Term loan period	4 years
Prepayments on term loan	125,000
Minimum amount of cash specified against payment of revolving loans	5,000,000
Minimum [Member]
Warranty on Product Sales [Line Items]
Period of warranty on product sales	1 year
Extended period of warranty on domestic sale of laser equipment	3 years
Maximum [Member]
Warranty on Product Sales [Line Items]
Period of warranty on product sales	2 years
Extended period of warranty on domestic sale of laser equipment	4 years
Maximum [Member] | Term Loan [Member]
Business Acquisition [Line Items]
Outstanding principal amount	10,000,000
Forbearance Agreement [Member]
Business Acquisition [Line Items]
Possible increase in interest (in hundredths)	2.00%
Maximum capital expenditures on medical devices	100,000
Lenders fee	500,000
Prepayments on term loan	250,000
Percentage of exceeded cash on hand to be paid against revolving loans (in hundredths)	100.00%
Minimum amount of cash specified against payment of revolving loans	7,000,000
Percentage of accrued and earned lender's fee for remaining period (in hundredths)	50.00%
Forbearance Agreement [Member] | CB Floating Rate [Member]
Business Acquisition [Line Items]
Effective interest rate (in hundredths)	4.00%
LCA Vision Inc [Member]
Business Acquisition [Line Items]
Percentage of shares acquired by wholly-owned subsidiary (in hundredths)	100.00%			100.00%
Effective date of merger	12-May-14
Cash consideration from sale of business				40,000,000
Net proceeds realized from sale of business				$37,700,000

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Jan. 31, 2015
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Estimated loss on sale from discontinued operations	($41,000)	$0
Loss from discontinued operations	-1,667,000	0
Stock based compensation expense of discontinued operations	2,363,000
LCA Vision Inc [Member]
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Percentage of shares acquired by wholly-owned subsidiary (in hundredths)	100.00%
Amount received after sale of business	40,000,000
Net proceeds, loss on the sale of discontinued operations				37,700,000
Estimated loss on sale from discontinued operations			44,598,000
Decrease in the implied fair value of goodwill	41,000,000		43,091,000
Revenues at discontinued operations	9,158,000
Loss from discontinued operations	1,667,000
Stock based compensation expense of discontinued operations	2,363,000
Disposal Group, Including Discontinued Operation, Assets [Abstract]
Cash and cash equivalents			4,514,000
Accounts receivable			2,759,000
Inventories			119,000
Deferred tax assets			1,930,000
Other current assets			2,492,000
Property & Equipment, net			14,519,000
Goodwill, net			6,491,000
Other intangible assets, net			38,331,000
Other assets			1,207,000
Assets held for sale			72,362,000
Less: Impairment			-1,507,000
Assets held for sale, net			70,855,000
Disposal Group, Including Discontinued Operation, Liabilities [Abstract]
Accounts payable			5,518,000
Other accrued liabilities			5,933,000
Deferred revenues			97,000
Long term debt			1,080,000
Other liabilities			6,870,000
Deferred tax liability			14,999,000
Liabilities held for sale			34,497,000
Total net assets of discontinued operations			$36,358,000

Acquisition_Details

Acquisition (Details) (USD $)	3 Months Ended
	Mar. 31, 2015		Dec. 31, 2014	Jan. 31, 2015	12-May-14
Business Acquisition [Line Items]
Common stock, outstanding (in shares)	22,076,718		20,376,245
Goodwill	$23,404,000		$24,048,000
LCA Vision Inc [Member]
Business Acquisition [Line Items]
Effective date of merger	12-May-14
Percentage of shares acquired by wholly-owned subsidiary (in hundredths)	100.00%			100.00%
Fair value LCA-Vision stock	103,896,000	[1]
Fair value of LCA-Vision restricted stock units, including payroll taxes	2,656,000	[2]
Total purchase price	106,552,000
Common stock, outstanding (in shares)					19,347,554
Restricted stock, outstanding or deemed to be outstanding (in shares)					476,436
Goodwill					49,582,000
Fair value of the assets acquired and liabilities assumed [Abstract]
Cash and cash equivalents					29,042,000
Current assets, excluding cash and cash equivalents					6,114,000
Deferred tax asset, current					1,124,000
Property, plant and equipment					17,269,000
Identifiable intangible assets					39,050,000
Other assets					1,518,000
Total assets acquired at fair value					94,117,000
Current liabilities					-19,009,000
Long-term debt					-1,603,000
Deferred tax liability, long-term					-9,138,000
Other long-term liabilities					-7,397,000
Total liabilities assumed					-37,147,000
Net assets acquired					56,970,000
Cash consideration from sale of business				40,000,000
Net proceeds, loss on the sale of discontinued operations				$37,700,000
[1]	Based on 19,347,554 outstanding shares of LCA-Vision common stock at May 12, 2014.
[2]	Based on 476,436 outstanding or deemed to be outstanding restricted stock units of LCA-Vision common stock at May 12, 2014.

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Schedule of inventories [Abstract]
Raw materials and work in progress	$7,699	$7,483
Finished goods	12,164	11,897
Total inventories	$19,863	$19,380

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Schedule property and equipment [Abstract]
Property and equipment, gross	$26,868		$25,092
Accumulated depreciation and amortization	-12,321		-11,290
Property and equipment, net	14,547		13,802
Depreciation and related amortization expense	1,052	824
Lasers-in-Service [Member]
Schedule property and equipment [Abstract]
Property and equipment, gross	20,725		18,974
Equipment, Computer Hardware and Software [Member]
Schedule property and equipment [Abstract]
Property and equipment, gross	4,902		4,870
Furniture and Fixtures [Member]
Schedule property and equipment [Abstract]
Property and equipment, gross	764		767
Leasehold Improvements [Member]
Schedule property and equipment [Abstract]
Property and equipment, gross	$477		$481

Patents_and_Licensed_Technolog2

Patents and Licensed Technologies, net (Details) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Patents and Licensed Technologies [Abstract]
Patents and licensed technologies, net	$8,253		$8,811
Estimated amortization expense for amortizable patents and licensed technologies assets [Abstract]
Patents and licensed technologies, net	8,253		8,811
Patents and Licensed Technologies [Member]
Patents and Licensed Technologies [Abstract]
Gross Amount beginning of period	15,626	15,648	15,648
Additions	29		168
Translation differences	-139		-190
Gross Amount end of period	15,516		15,626
Accumulated amortization	-7,263		-6,815
Patents and licensed technologies, net	8,253		8,811
Amortization expense	513	512
Estimated amortization expense for amortizable patents and licensed technologies assets [Abstract]
Last nine months of 2015	1,544
2016	2,021
2017	885
2018	908
2019	894
Thereafter	2,001
Patents and licensed technologies, net	$8,253		$8,811

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Details) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Goodwill [Roll Forward]
Goodwill, beginning balance	$24,048
Translation differences	-644
Goodwill, ending balance	23,404		24,048
Accumulated impairment loss	0
Schedule of definite-lived intangible assets [Abstract]
Gross Amount beginning of period	11,981	12,189	12,189
Translation differences	-151		-208
Gross Amount end of period	11,830		11,981
Accumulated amortization	-3,894		-3,644
Net Book Value	7,936		8,337
Amortization expense	300	300
Estimated amortization expense for amortizable intangible assets [Abstract]
Last nine months of 2015	900
2016	1,200
2017	1,200
2018	1,200
2019	1,200
Thereafter	2,236
Net Book Value	7,936		8,337
Trademarks [Member]
Schedule of definite-lived intangible assets [Abstract]
Gross Amount beginning of period	5,692	5,772	5,772
Translation differences	-57		-80
Gross Amount end of period	5,635		5,692
Accumulated amortization	-1,855		-1,731
Net Book Value	3,780		3,961
Estimated amortization expense for amortizable intangible assets [Abstract]
Net Book Value	3,780		3,961
Customer Relationships [Member]
Schedule of definite-lived intangible assets [Abstract]
Gross Amount beginning of period	6,289	6,417	6,417
Translation differences	-94		-128
Gross Amount end of period	6,195		6,289
Accumulated amortization	-2,039		-1,913
Net Book Value	4,156		4,376
Estimated amortization expense for amortizable intangible assets [Abstract]
Net Book Value	4,156		4,376
Radiancy, Inc. [Member]
Goodwill [Line Items]
Definite-lived intangible assets recorded as a part of purchase price allocation	12,000
Goodwill [Roll Forward]
Goodwill, ending balance	$24,005

Accrued_Compensation_and_relat2

Accrued Compensation and related expenses (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Accrued Compensation and related expenses [Abstract]
Accrued payroll and related taxes	$620	$513
Accrued vacation	410	211
Accrued commissions and bonuses	1,781	1,898
Total accrued compensation and related expense	$2,811	$2,622

Other_Accrued_Liabilities_Deta

Other Accrued Liabilities (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015		Mar. 31, 2014	Dec. 31, 2014
Other Accrued Liabilities [Abstract]
Accrued warranty, current, see Note 1	$673		$1,021	$665
Accrued taxes, net	1,534			1,362
Accrued sales returns	5,941	[1]	9,773
Other accrued liabilities	2,223			3,344
Total other accrued liabilities	10,371			13,022
Sales returns liability roll forward [Abstract]
Balance at beginning of year	7,651	[1]	16,046
Additions that reduce net sales	6,519		9,899
Deductions from reserves	-8,229		-16,172
Balance at end of period	$5,941	[1]	$9,773
[1]	The activity in the accrued sales returns liability account was as follows: March 31, 2015 2014 Balance at beginning of year $ 7,651 $ 16,046 Additions that reduce net sales 6,519 9,899 Deductions from reserves (8,229) (16,172) Balance at end of year $ 5,941 $ 9,773

Longterm_Debt_Details

Long-term Debt (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Total	$40,018,000
Less: current portion	-3,000,000	-38,732,000
Long-term Debt	37,018,000	37,768,000
Principal payments on the loan	36,482,000
Forbearance fees	1,481,000
Future minimum payment for long-term debt [Abstract]
Last nine months of 2015	2,250,000
2016	37,768,000
Total	40,018,000
Forbearance Agreement [Member]
Debt Instrument [Line Items]
Prepayments on term loan	250,000,000
Percentage of exceeded cash on hand to be paid against revolving loans (in hundredths)	100.00%
Minimum amount of cash specified against payment of revolving loans	7,000,000
Maximum capital expenditures on medical devices	100,000
Revolving loans payable	500,000,000
Percentage of accrued and earned lender's fee for remaining period (in hundredths)	50.00%
Lenders fee	500,000
Possible increase in interest (in hundredths)	2.00%
Fee Payment Each Month For May and June 2015 [Member]
Debt Instrument [Line Items]
Lenders fee	750,000
Fee Payment Each Month For July Through September 2015 [Member]
Debt Instrument [Line Items]
Lenders fee	1,000,000
Fee Payment Each Month For October Through December 2015 [Member]
Debt Instrument [Line Items]
Lenders fee	1,250,000
Fee Payment Each Month For January Through March 2016 [Member]
Debt Instrument [Line Items]
Lenders fee	1,500,000
CB Floating Rate [Member] | Forbearance Agreement [Member]
Debt Instrument [Line Items]
Effective interest rate (in hundredths)	4.00%
Senior-Secured Credit Facilities [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	85,000,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	10,000,000
Term Loan [Member]
Debt Instrument [Line Items]
Total	40,018,000	76,500,000
Maximum borrowing capacity	75,000,000
Prepayments on term loan	125,000,000
Minimum amount of cash specified against payment of revolving loans	5,000,000
Description of variable rate basis	Eurodollar
Repayment period	4 years
Future minimum payment for long-term debt [Abstract]
Total	40,018,000	76,500,000
Minimum [Member] | Term Loan [Member] | Eurodollar [Member]
Debt Instrument [Line Items]
Effective interest rate (in hundredths)	3.25%
Maximum [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Outstanding principal amount	$10,000,000
Maximum [Member] | Term Loan [Member] | Eurodollar [Member]
Debt Instrument [Line Items]
Effective interest rate (in hundredths)	4.50%

Income_Taxes_Details

Income Taxes (Details)	3 Months Ended
	Mar. 31, 2015
Effective income tax rate reconciliation [Line Items]
Statutory income tax rate (in hundredths)	34.00%
Percentage of valuation allowance (in hundredths)	100.00%
Israeli Subsidiaries [Member]
Effective income tax rate reconciliation [Line Items]
Standard corporate income tax rate (in hundredths)	26.50%
UK Subsidiaries [Member]
Effective income tax rate reconciliation [Line Items]
Standard corporate income tax rate (in hundredths)	20.00%

Commitments_and_contingencies_

Commitments and contingencies (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
	Customer
	State
	Executive
Loss Contingencies [Line Items]
Number of executives	2
Court awarded settlement amount	$1,500,000
Number of customers	12
Number of states	10
Maximum [Member]
Loss Contingencies [Line Items]
Company contribution to settlement	$100,000

Employee_Stock_Benefit_Plans_D

Employee Stock Benefit Plans (Details) (USD $)	3 Months Ended		0 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Feb. 26, 2015
Weighted Average Exercise Price [Roll Forward]
Unrecognized compensation cost related to non-vested option grants and stock awards	$7,260
Unrecognized compensation cost expected to recognized	3 years 4 months 24 days
Total stock based compensation expense	3,337	1,262
Stock based compensation expense of discontinued operations	2,363
Stock Options [Member]
Number of Options [Roll Forward]
Outstanding (in shares)	1,159,554
Granted (in shares)	0
Exercised (in shares)	0
Cancelled (in shares)	-180,116
Outstanding (in shares)	979,438
Options exercisable (in shares)	626,138
Weighted Average Exercise Price [Roll Forward]
Outstanding (in dollars per share)	$16.23
Granted (in dollars per share)	$0
Exercised (in dollars per share)	$0
Cancelled (in dollars per share)	$15.39
Outstanding (in dollars per share)	$16.38
Options exercisable (in dollars per share)	$16.23
Restricted Stock [Member] | Employees [Member]
Weighted Average Exercise Price [Roll Forward]
Restricted stock units granted (in shares)			1,495,000
Price of restricted stock (in dollars per share)			$0.01
Stock options expiration period			4 years
Aggregate fair value			$2,766
Non-Employee Director Stock Option Plan [Member]
Common Stock Options [Abstract]
Authorized shares (in shares)	370,000
Stock reserved for issuance to eligible employees (in shares)	7,000
Shares reserved for future issuance under stock option (in shares)	12,912
One time stock issuance after reverse merger (in shares)	5,000
2005 Equity Plan [Member]
Common Stock Options [Abstract]
Authorized shares (in shares)	6,000,000
Shares reserved for future issuance under stock option (in shares)	966,526
Shares reserved for future issuance under common stock (in shares)	3,071,095

Business_Segments_and_Geograph2

Business Segments and Geographic Data (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
	Segment
Business Segments and Geographic Data [Abstract]
Number of operating units	3
Results of operations from business segments [Abstract]
Revenues	$28,149	$50,075
Costs of revenues	7,922	10,345
Gross profit	20,227	39,730
Gross profit % (in hundredths)	71.90%	79.30%
Allocated operating expenses [Abstract]
Engineering and product development	755	795
Selling and marketing expenses	20,132	31,625
Unallocated operating expenses	4,729	7,587
Total operating expenses	25,616	40,007
Loss from continuing operations before interest and other financing expense, net	-5,389	-277
Interest and other financing income, net	-2,551	-147
(Loss) Income before income tax benefit (expense)	-7,940	-424
Operating Segments [Member] | Consumer [Member]
Results of operations from business segments [Abstract]
Revenues	18,129	40,870
Costs of revenues	3,497	6,250
Gross profit	14,632	34,620
Gross profit % (in hundredths)	80.70%	84.70%
Allocated operating expenses [Abstract]
Engineering and product development	338	287
Selling and marketing expenses	14,719	27,157
Unallocated operating expenses	0	0
Total operating expenses	15,057	27,444
Loss from continuing operations before interest and other financing expense, net	-425	7,176
Interest and other financing income, net	0	0
(Loss) Income before income tax benefit (expense)	-425	7,176
Operating Segments [Member] | Physician Recurring [Member]
Results of operations from business segments [Abstract]
Revenues	7,558	7,219
Costs of revenues	2,777	2,830
Gross profit	4,781	4,389
Gross profit % (in hundredths)	63.30%	60.80%
Allocated operating expenses [Abstract]
Engineering and product development	321	310
Selling and marketing expenses	5,191	4,011
Unallocated operating expenses	0	0
Total operating expenses	5,512	4,321
Loss from continuing operations before interest and other financing expense, net	-731	68
Interest and other financing income, net	0	0
(Loss) Income before income tax benefit (expense)	-731	68
Operating Segments [Member] | Professional [Member]
Results of operations from business segments [Abstract]
Revenues	2,462	1,986
Costs of revenues	1,648	1,265
Gross profit	814	721
Gross profit % (in hundredths)	33.10%	36.30%
Allocated operating expenses [Abstract]
Engineering and product development	96	198
Selling and marketing expenses	222	457
Unallocated operating expenses	0	0
Total operating expenses	318	655
Loss from continuing operations before interest and other financing expense, net	496	66
Interest and other financing income, net	0	0
(Loss) Income before income tax benefit (expense)	$496	$66

Business_Segment_and_Geographi

Business Segment and Geographic Data, Revenue by Geographical Data (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015		Mar. 31, 2014		Dec. 31, 2014
Net revenues by geographic area [Abstract]
Revenues	$28,149		$50,075
Long-lived assets by geographic area [Abstract]
Long-lived assets	14,547				13,802
Reportable Geographical Components [Member] | North America [Member]
Net revenues by geographic area [Abstract]
Revenues	20,764	[1]	39,972	[1]
Long-lived assets by geographic area [Abstract]
Long-lived assets	13,169				12,385
Reportable Geographical Components [Member] | Asia Pacific [Member]
Net revenues by geographic area [Abstract]
Revenues	2,371	[2]	2,377	[2]
Long-lived assets by geographic area [Abstract]
Long-lived assets	310				286
Reportable Geographical Components [Member] | Europe (Including Israel) [Member]
Net revenues by geographic area [Abstract]
Revenues	4,899		7,408
Long-lived assets by geographic area [Abstract]
Long-lived assets	1,065				1,127
Reportable Geographical Components [Member] | South America [Member]
Net revenues by geographic area [Abstract]
Revenues	115		318
Long-lived assets by geographic area [Abstract]
Long-lived assets	3				4
Reportable Geographical Components [Member] | United States [Member]
Net revenues by geographic area [Abstract]
Revenues	18,678		34,766
Reportable Geographical Components [Member] | Canada [Member]
Net revenues by geographic area [Abstract]
Revenues	2,062		5,206
Reportable Geographical Components [Member] | Japan [Member]
Net revenues by geographic area [Abstract]
Revenues	$91		$698
[1]	United States $18,678 $34,766 Canada $2,062 $5,206
[2]	Japan $91 $698

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	3 Months Ended	1 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
		Model
Subsequent Event [Line Items]
Lease Expiration Date	30-Sep-17
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of new product model launched		2
Initial stocking order value for immediate shipment		$1,200,000
Extended lease term		24 months
Monthly base rent for first twelve months		16,227
Monthly base rent for last twelve months		16,714
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Lease improvement allowance		$42,000